CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | fluorobenzenes |
|
Accession: | CHEBI:35496
|
browse the term
|
Definition: | Any fluoroarene that is a benzene or a substituted benzene carrying at least one fluoro group. |
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases chemical synthesis increases glucuronidation multiple interactions increases abundance |
ISO |
CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam CYP3A4 protein results in increased glucuronidation of 1-hydroxymethylmidazolam [[3-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[5-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[6-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[6-methylflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[7-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[alpha-naphthoflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[artemetin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[beta-Naphthoflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[chrysin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[eupatilin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[flavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[galangin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[nobiletin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[sinensetin analog results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[sinensetin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[tangeretin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [CYP3A4 protein results in increased glucuronidation of 1-hydroxymethylmidazolam] which results in increased abundance of 1-hydroxymethylmidazolam glucuronide; [CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased abundance of 1-hydroxymethylmidazolam; [CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [Ketoconazole results in decreased activity of CYP3A4 protein] which results in decreased chemical synthesis of 1-hydroxymethylmidazolam; [L 754394 results in decreased activity of CYP3A4 protein] which results in decreased chemical synthesis of 1-hydroxymethylmidazolam; acacetin promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Apigenin promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 1-hydroxymethylmidazolam]; diosmetin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; flavanone promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; flavone promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; galangin promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased abundance of 1-hydroxymethylmidazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Luteolin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]]; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Verapamil inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam] |
CTD |
PMID:10997946 PMID:12401345 PMID:12695342 PMID:18191104 PMID:20233841 PMID:21053930 PMID:21915887 PMID:23850985 PMID:26958860 PMID:27485346 PMID:30087611 PMID:31756459 PMID:34189909 More...
|
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases chemical synthesis multiple interactions |
ISO |
CYP3A5 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam [CYP3A5 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; erdafitinib inhibits the reaction [[CYP3A5 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam] |
CTD |
PMID:18191104 PMID:26958860 PMID:34189909 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Tspo |
translocator protein |
affects binding |
EXP |
1-hydroxymethylmidazolam binds to TSPO protein; 1-hydroxymethylmidazolam metabolite binds to TSPO protein |
CTD |
PMID:7603229 |
|
NCBI chr 7:114,720,188...114,730,450
Ensembl chr 7:114,720,188...114,730,450
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[CYP3A4 protein results in increased glucuronidation of 1-hydroxymethylmidazolam] which results in increased abundance of 1-hydroxymethylmidazolam glucuronide |
CTD |
PMID:27485346 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases chemical synthesis multiple interactions |
ISO |
CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam [CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased abundance of 4-hydroxymidazolam; [CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam; acacetin inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; Apigenin inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 4-hydroxymidazolam]; diosmetin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; flavanone inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; flavone inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; galangin inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Luteolin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:12695342 PMID:18191104 PMID:21053930 PMID:27485346 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases chemical synthesis multiple interactions |
ISO |
CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam diosmetin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Luteolin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
ISO |
amperozide inhibits the reaction [KCNH2 protein results in increased transport of Thallium] |
CTD |
PMID:19583963 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
atorvastatin co-treated with N-nitrosodiethylamine increases expression of Cdh1 mRNA in liver |
RGD |
PMID:25319454 |
RGD:152995431 |
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
decreases expression |
ISO |
atorvastatin co-treated with N-nitrosodiethylamine decreases expression of Slco1b2 mRNA in liver |
RGD |
PMID:25319454 |
RGD:152995431 |
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Azaperone results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
|
G |
Aamp |
angio-associated, migratory cell protein |
increases expression |
ISO |
bicalutamide results in increased expression of AAMP mRNA |
CTD |
PMID:16631469 |
|
NCBI chr 9:75,863,382...75,869,188
Ensembl chr 9:75,863,389...75,868,547
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
bicalutamide results in decreased activity of ABCB11 protein |
CTD |
PMID:28437613 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
bicalutamide results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Acp3 |
acid phosphatase 3 |
decreases expression |
ISO |
bicalutamide results in decreased expression of ACP3 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
increases expression |
ISO |
bicalutamide results in increased expression of ACSL1 mRNA |
CTD |
PMID:15790403 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Adam9 |
ADAM metallopeptidase domain 9 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of ADAM9 protein] |
CTD |
PMID:17342749 |
|
NCBI chr16:67,022,538...67,101,647
Ensembl chr16:67,022,655...67,100,917
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
decreases expression multiple interactions |
ISO |
bicalutamide results in decreased expression of ADRB2 mRNA; bicalutamide results in decreased expression of ADRB2 protein bicalutamide inhibits the reaction [Triiodothyronine results in increased expression of ADRB2 protein] |
CTD |
PMID:18454446 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Agr2 |
anterior gradient 2, protein disulphide isomerase family member |
increases expression |
ISO |
bicalutamide results in increased expression of AGR2 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 6:52,708,602...52,729,378
Ensembl chr 6:52,708,602...52,729,371
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Metribolone results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:17325745 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of ALDH1A3 mRNA] |
CTD |
PMID:17526768 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
increases expression |
ISO |
bicalutamide results in increased expression of ALDH3A2 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281
|
|
G |
Amacr |
alpha-methylacyl-CoA racemase |
decreases expression |
ISO |
bicalutamide results in decreased expression of AMACR mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 2:59,946,158...59,958,255
Ensembl chr 2:59,946,153...59,958,255
|
|
G |
Amd1 |
adenosylmethionine decarboxylase 1 |
increases expression |
ISO |
bicalutamide results in increased expression of AMD1 mRNA |
CTD |
PMID:15790403 |
|
NCBI chr20:43,695,783...43,711,476
Ensembl chr20:43,697,237...43,711,476
|
|
G |
Ankib1 |
ankyrin repeat and IBR domain containing 1 |
increases expression |
ISO |
bicalutamide results in increased expression of ANKIB1 mRNA |
CTD |
PMID:16631469 |
|
NCBI chr 4:30,333,678...30,457,781
Ensembl chr 4:30,333,677...30,457,781
|
|
G |
Ar |
androgen receptor |
decreases response to substance decreases expression multiple interactions increases expression decreases activity affects binding affects response to substance affects localization |
ISO EXP |
AR gene mutant form results in decreased susceptibility to bicalutamide; AR protein alternative form results in decreased susceptibility to bicalutamide bicalutamide results in decreased expression of AR protein bicalutamide binds to and results in decreased activity of AR protein; bicalutamide inhibits the reaction [[Testosterone binds to AR protein] inhibits the reaction [Dexamethasone results in increased expression of DDIT4 mRNA]] bicalutamide results in increased localization of and results in increased activity of AR protein bicalutamide results in increased expression of AR; bicalutamide results in increased expression of AR protein bicalutamide results in decreased expression of AR; bicalutamide results in decreased expression of AR mRNA bicalutamide results in decreased activity of AR protein [bicalutamide binds to AR protein] which binds to KLK3 promoter; bicalutamide binds to AR protein AR protein affects the susceptibility to bicalutamide [Azacitidine analog results in increased expression of AR protein] which results in increased susceptibility to bicalutamide; [bicalutamide binds to and results in decreased activity of AR protein] inhibits the reaction [Dehydroepiandrosterone results in decreased expression of CYP1A2 mRNA]; [bicalutamide co-treated with Testosterone] affects the expression of and results in decreased activity of AR protein; [bicalutamide results in decreased susceptibility to bicalutamide] which results in increased expression of and affects the localization of AR protein alternative form; [bicalutamide results in decreased susceptibility to bicalutamide] which results in increased expression of AR mRNA; [bicalutamide results in decreased susceptibility to bicalutamide] which results in increased expression of AR mRNA alternative form; [bicalutamide results in decreased susceptibility to bicalutamide] which results in increased expression of AR protein; [Dihydrotestosterone co-treated with bicalutamide] promotes the reaction [AR protein binds to PHB1 protein]; [Dihydrotestosterone co-treated with bicalutamide] promotes the reaction [AR protein binds to SMARCA4 protein]; [Goserelin co-treated with bicalutamide] results in decreased expression of AR protein; [Goserelin co-treated with Dutasteride co-treated with bicalutamide co-treated with Ketoconazole] results in decreased expression of AR protein; [Goserelin co-treated with Dutasteride co-treated with bicalutamide] results in decreased expression of AR protein; AR protein promotes the reaction [bicalutamide promotes the reaction [PHB1 protein binds to KLK3 promoter]]; bicalutamide affects the reaction [beta-hexachlorocyclohexane affects the expression of AR protein]; bicalutamide affects the reaction [Testosterone affects the expression of AR protein]; bicalutamide binds to and affects the localization of and affects the activity of AR protein; bicalutamide binds to and results in decreased activity of AR protein; bicalutamide binds to and results in increased activity of AR protein mutant form; bicalutamide inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; bicalutamide inhibits the reaction [[Dihydrotestosterone binds to and results in increased activity of AR protein] which results in increased expression of KLK3 protein]; bicalutamide inhibits the reaction [[Metribolone binds to and results in increased activity of AR protein] which results in increased expression of KLK3 protein]; bicalutamide inhibits the reaction [alpha-naphthoflavone inhibits the reaction [Particulate Matter analog inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]]]; bicalutamide inhibits the reaction [alpha-naphthoflavone inhibits the reaction [Vehicle Emissions analog inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]]]; bicalutamide inhibits the reaction [AR protein alternative form binds to KLK3 promoter]; bicalutamide inhibits the reaction [AR protein alternative form promotes the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]]; bicalutamide inhibits the reaction [AR protein binds to KLK3 promoter]; bicalutamide inhibits the reaction [AR protein binds to NCOA1 protein]; bicalutamide inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]]; bicalutamide inhibits the reaction [Cadmium Chloride results in decreased expression of AR mRNA]; bicalutamide inhibits the reaction [Cadmium Chloride results in decreased expression of AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone affects the localization of AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone binds to AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone promotes the reaction [AR protein binds to MYC enhancer]]; bicalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of AR mRNA]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein mutant form]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of and results in increased phosphorylation of AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; bicalutamide inhibits the reaction [Estradiol results in increased activity of AR protein mutant form]; bicalutamide inhibits the reaction [Estradiol results in increased activity of AR protein]; bicalutamide inhibits the reaction [Fludrocortisone results in increased activity of AR protein mutant form]; bicalutamide inhibits the reaction [Flutamide results in increased activity of AR protein mutant form]; bicalutamide inhibits the reaction [Metribolone results in increased activity of AR protein mutant form]; bicalutamide inhibits the reaction [Metribolone results in increased activity of AR protein]; bicalutamide inhibits the reaction [Metribolone results in increased folding of and results in increased stability of AR protein]; bicalutamide inhibits the reaction [OSM protein results in increased activity of AR protein]; bicalutamide inhibits the reaction [Sirolimus results in increased activity of AR protein]; bicalutamide inhibits the reaction [Testosterone results in increased activity of AR protein]; bicalutamide promotes the reaction [AR protein binds to KLK3 promoter]; bicalutamide promotes the reaction [AR protein binds to NCOR2 protein]; bicalutamide promotes the reaction [Niclosamide inhibits the reaction [AR protein binds to KLK3 promoter]]; bicalutamide promotes the reaction [Niclosamide results in decreased expression of AR protein alternative form]; bicalutamide promotes the reaction [Niclosamide results in decreased expression of AR protein]; methoxyacetic acid inhibits the reaction [bicalutamide inhibits the reaction [Testosterone results in increased activity of AR protein]]; mibolerone inhibits the reaction [bicalutamide results in increased expression of AR protein]; Resveratrol promotes the reaction [bicalutamide results in decreased activity of AR protein] bicalutamide affects the localization of AR protein |
CTD |
PMID:10053169 PMID:11751618 PMID:11845989 PMID:11956172 PMID:11981028 PMID:12015321 PMID:12114440 PMID:12376534 PMID:12730620 PMID:12970580 PMID:15171712 PMID:15308689 PMID:15336702 PMID:15638997 PMID:15994348 PMID:16015592 PMID:16266977 PMID:16877366 PMID:17606915 PMID:17723170 PMID:17804755 PMID:18324645 PMID:18324785 PMID:18486176 PMID:18487222 PMID:18776922 PMID:18922931 PMID:19131511 PMID:19359544 PMID:19587329 PMID:20032058 PMID:20729295 PMID:21036700 PMID:21308717 PMID:21506597 PMID:23562765 PMID:23603339 PMID:24323034 PMID:24759320 PMID:25752796 PMID:26867867 PMID:27473015 PMID:27720946 PMID:28500234 PMID:28757136 PMID:29383186 PMID:29427707 PMID:29462692 PMID:33049310 PMID:33207735 More...
|
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arg1 |
arginase 1 |
decreases expression |
ISO |
bicalutamide results in decreased expression of ARG1 protein |
CTD |
PMID:20711410 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arg2 |
arginase 2 |
increases expression |
ISO |
bicalutamide results in increased expression of ARG2 protein |
CTD |
PMID:20711410 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Asap2 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 |
increases expression |
ISO |
bicalutamide results in increased expression of ASAP2 mRNA |
CTD |
PMID:16631469 |
|
NCBI chr 6:40,658,201...40,821,017
Ensembl chr 6:40,657,880...40,820,975
|
|
G |
Atf3 |
activating transcription factor 3 |
decreases expression increases expression |
ISO |
bicalutamide results in decreased expression of ATF3 protein bicalutamide results in increased expression of ATF3 mRNA |
CTD |
PMID:15638997 PMID:16516039 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atp5me |
ATP synthase membrane subunit e |
increases expression |
ISO |
bicalutamide results in increased expression of ATP5ME mRNA |
CTD |
PMID:16631469 |
|
NCBI chr14:1,319,868...1,320,996
Ensembl chr14:1,319,868...1,321,013
|
|
G |
B4galt6 |
beta-1,4-galactosyltransferase 6 |
increases expression |
ISO |
bicalutamide results in increased expression of B4GALT6 mRNA |
CTD |
PMID:16631469 |
|
NCBI chr18:11,958,382...12,015,247
Ensembl chr18:11,958,390...12,015,247
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
decreases expression |
ISO |
bicalutamide results in decreased expression of BARD1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression increases expression multiple interactions |
ISO |
bicalutamide results in decreased expression of BAX bicalutamide results in increased expression of BAX protein [bicalutamide co-treated with Curcumin co-treated with Quercetin] results in increased expression of BAX protein; [Niclosamide co-treated with bicalutamide] results in increased expression of BAX protein; bicalutamide inhibits the reaction [Niclosamide results in decreased expression of BAX protein] |
CTD |
PMID:11845989 PMID:27132804 PMID:28500234 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bche |
butyrylcholinesterase |
decreases expression |
ISO |
bicalutamide results in decreased expression of BCHE mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
ISO |
bicalutamide results in increased expression of BCL2 bicalutamide promotes the reaction [Niclosamide results in decreased expression of BCL2 protein]; Niclosamide promotes the reaction [bicalutamide results in decreased expression of BCL2 protein] |
CTD |
PMID:11845989 PMID:28500234 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
ISO |
bicalutamide results in decreased expression of BCL2L1 protein bicalutamide promotes the reaction [Niclosamide results in decreased expression of BCL2L1 protein]; Niclosamide promotes the reaction [bicalutamide results in decreased expression of BCL2L1 protein] |
CTD |
PMID:28500234 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
bicalutamide results in decreased expression of BIRC5 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
ISO |
bicalutamide results in increased expression of BNIP3 mRNA |
CTD |
PMID:15790403 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Btbd3 |
BTB domain containing 3 |
increases expression |
ISO |
bicalutamide results in increased expression of BTBD3 mRNA |
CTD |
PMID:16631469 |
|
NCBI chr 3:125,591,427...125,621,660
Ensembl chr 3:125,591,490...125,619,038
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
decreases expression |
ISO |
bicalutamide results in decreased expression of BUB1B mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[bicalutamide co-treated with Curcumin co-treated with Quercetin] results in increased expression of CASP3 protein; bicalutamide results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:15638997 PMID:27132804 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
bicalutamide promotes the reaction [Niclosamide results in increased expression of CASP7 protein modified form] |
CTD |
PMID:28500234 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]] |
CTD |
PMID:16317058 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
bicalutamide results in decreased expression of CCNA2 mRNA |
CTD |
PMID:15887248 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
bicalutamide results in decreased expression of CCNB1 mRNA |
CTD |
PMID:15887248 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb1ip1 |
cyclin B1 interacting protein 1 |
increases expression |
ISO |
bicalutamide results in increased expression of CCNB1IP1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr15:24,014,905...24,031,357
Ensembl chr15:24,014,908...24,028,475
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
Niclosamide promotes the reaction [bicalutamide results in decreased expression of CCND1 protein] |
CTD |
PMID:28500234 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccng2 |
cyclin G2 |
increases expression |
ISO |
bicalutamide results in increased expression of CCNG2 mRNA |
CTD |
PMID:15790403 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Ccpg1 |
cell cycle progression 1 |
increases expression |
ISO |
bicalutamide results in increased expression of CCPG1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]] |
CTD |
PMID:16317058 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd9 |
CD9 molecule |
increases expression |
ISO |
bicalutamide results in increased expression of CD9 mRNA |
CTD |
PMID:15790403 |
|
NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression |
ISO |
bicalutamide results in decreased expression of CDC20 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
ISO |
bicalutamide results in decreased expression of CDC6 mRNA; bicalutamide results in decreased expression of CDC6 protein |
CTD |
PMID:15887248 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdh1 |
cadherin 1 |
affects localization |
ISO |
bicalutamide affects the localization of CDH1 protein |
CTD |
PMID:17440980 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
bicalutamide results in decreased expression of CDK1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
bicalutamide results in increased expression of CDKN1A; bicalutamide results in increased expression of CDKN1A mRNA; bicalutamide results in increased expression of CDKN1A protein [bicalutamide co-treated with Curcumin co-treated with Quercetin] results in increased expression of CDKN1A protein |
CTD |
PMID:11845989 PMID:15638997 PMID:27132804 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
bicalutamide results in increased expression of CDKN1B |
CTD |
PMID:11845989 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
decreases expression |
ISO |
bicalutamide results in decreased expression of CDKN2C mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
decreases expression |
ISO |
bicalutamide results in decreased expression of CKS2 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr17:13,570,611...13,575,770
|
|
G |
Clgn |
calmegin |
increases expression |
ISO |
bicalutamide results in increased expression of CLGN mRNA |
CTD |
PMID:15638997 |
|
NCBI chr19:24,695,140...24,728,542
Ensembl chr19:24,696,875...24,728,758
|
|
G |
Clu |
clusterin |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Metribolone results in increased expression of CLU mRNA]; bicalutamide inhibits the reaction [Metribolone results in increased expression of CLU protein] |
CTD |
PMID:17148459 PMID:17325745 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Copb2 |
COPI coat complex subunit beta 2 |
increases expression |
ISO |
bicalutamide results in increased expression of COPB2 mRNA |
CTD |
PMID:16631469 |
|
NCBI chr 8:99,161,324...99,183,452
Ensembl chr 8:99,161,350...99,185,197
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Metribolone results in decreased expression of CREBBP protein] |
CTD |
PMID:15378487 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Cubn |
cubilin |
decreases expression multiple interactions |
EXP |
bicalutamide results in decreased expression of CUBN protein bicalutamide promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of CUBN protein] |
CTD |
PMID:35151640 |
|
NCBI chr17:76,385,046...76,593,133
Ensembl chr17:76,385,060...76,593,231
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
bicalutamide inhibits the reaction [Androstenedione results in increased expression of CYP11A1 protein]; bicalutamide inhibits the reaction [Testosterone results in increased expression of CYP11A1 protein] |
CTD |
PMID:21273442 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
bicalutamide inhibits the reaction [Androstenedione results in increased expression of CYP19A1 protein]; bicalutamide inhibits the reaction [Testosterone results in increased expression of CYP19A1 protein] |
CTD |
PMID:21273442 |
|
NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
bicalutamide results in decreased activity of CYP1A1 protein |
CTD |
PMID:34181028 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[bicalutamide binds to and results in decreased activity of AR protein] inhibits the reaction [Dehydroepiandrosterone results in decreased expression of CYP1A2 mRNA]; bicalutamide inhibits the reaction [Dehydroepiandrosterone results in increased degradation of CYP1A2 mRNA] |
CTD |
PMID:23603339 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
bicalutamide results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
multiple interactions |
EXP |
bicalutamide inhibits the reaction [[Testosterone binds to AR protein] inhibits the reaction [Dexamethasone results in increased expression of DDIT4 mRNA]] |
CTD |
PMID:20032058 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Deptor |
DEP domain containing MTOR-interacting protein |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of DEPTOR mRNA] |
CTD |
PMID:26558456 |
|
NCBI chr 7:86,514,859...86,668,817
Ensembl chr 7:86,514,988...86,667,773
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
increases expression |
ISO |
bicalutamide results in increased expression of DIO3 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dkc1 |
dyskerin pseudouridine synthase 1 |
decreases expression |
ISO |
bicalutamide results in decreased expression of DKC1 mRNA |
CTD |
PMID:15638997 |
|
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
increases expression |
ISO |
bicalutamide results in increased expression of DNAJB9 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Drd4 |
dopamine receptor D4 |
decreases expression multiple interactions |
ISO |
bicalutamide results in decreased expression of DRD4 mRNA FSHB protein inhibits the reaction [bicalutamide results in decreased expression of DRD4 protein] |
CTD |
PMID:19587329 |
|
NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
decreases expression |
ISO |
bicalutamide results in decreased expression of EBP mRNA |
CTD |
PMID:15638997 |
|
NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [FOS protein results in increased expression of EGF mRNA] |
CTD |
PMID:15466214 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]]; bicalutamide inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]; bicalutamide inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein] |
CTD |
PMID:29383186 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
[bicalutamide co-treated with Testosterone] results in decreased phosphorylation of EIF4EBP1 protein |
CTD |
PMID:21036700 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eppin |
epididymal peptidase inhibitor |
decreases expression multiple interactions |
ISO |
bicalutamide results in decreased expression of EPPIN mRNA FSHB protein inhibits the reaction [bicalutamide results in decreased expression of EPPIN protein] |
CTD |
PMID:19587329 |
|
NCBI chr 3:153,312,396...153,319,310
Ensembl chr 3:153,312,396...153,319,310
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
bicalutamide binds to and results in increased activity of ESR1 protein |
CTD |
PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]] |
CTD |
PMID:29383186 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Etl4 |
enhancer trap locus 4 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of KIAA1217 mRNA] |
CTD |
PMID:17624924 |
|
NCBI chr17:82,841,075...83,304,868
Ensembl chr17:82,495,041...83,304,715
|
|
G |
Etv1 |
ETS variant transcription factor 1 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of ETV1 mRNA] |
CTD |
PMID:28757136 |
|
NCBI chr 6:55,590,149...55,681,784
Ensembl chr 6:55,590,234...55,681,775
|
|
G |
Ezr |
ezrin |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Metribolone results in increased expression of EZR mRNA]; bicalutamide inhibits the reaction [Metribolone results in increased phosphorylation of EZR protein] |
CTD |
PMID:16873375 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of FABP4 protein] |
CTD |
PMID:18801408 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fgf13 |
fibroblast growth factor 13 |
increases expression |
ISO |
bicalutamide results in increased expression of FGF13 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr X:137,276,498...137,800,056
Ensembl chr X:137,276,511...137,800,391
|
|
G |
Fkbp11 |
FKBP prolyl isomerase 11 |
increases expression |
ISO |
bicalutamide results in increased expression of FKBP11 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 7:129,871,870...129,877,760
Ensembl chr 7:129,871,870...129,875,303
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
decreases expression multiple interactions |
ISO |
bicalutamide results in decreased expression of FKBP5 mRNA [Niclosamide co-treated with bicalutamide] results in decreased expression of FKBP5 mRNA |
CTD |
PMID:28500234 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of FOS mRNA]; bicalutamide inhibits the reaction [FOS protein results in increased expression of EGF mRNA] |
CTD |
PMID:15466214 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
ISO |
FSHB protein inhibits the reaction [bicalutamide results in decreased expression of DRD4 protein]; FSHB protein inhibits the reaction [bicalutamide results in decreased expression of EPPIN protein]; FSHB protein inhibits the reaction [bicalutamide results in decreased expression of GPD1 protein]; FSHB protein inhibits the reaction [bicalutamide results in decreased expression of RHOX5 protein] |
CTD |
PMID:19587329 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
bicalutamide results in increased expression of GADD45A mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gcg |
glucagon |
decreases expression |
ISO |
bicalutamide results in decreased expression of GCG mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 3:47,113,914...47,122,929
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Gpc1 |
glypican 1 |
decreases expression |
ISO |
bicalutamide results in decreased expression of GPC1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 9:93,396,234...93,424,047
Ensembl chr 9:93,396,234...93,424,047
|
|
G |
Gpd1 |
glycerol-3-phosphate dehydrogenase 1 |
decreases expression multiple interactions |
ISO |
bicalutamide results in decreased expression of GPD1 mRNA FSHB protein inhibits the reaction [bicalutamide results in decreased expression of GPD1 protein] |
CTD |
PMID:19587329 |
|
NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529
|
|
G |
Gpnmb |
glycoprotein nmb |
increases expression |
ISO |
bicalutamide results in increased expression of GPNMB mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
|
|
G |
Gprc5a |
G protein-coupled receptor, class C, group 5, member A |
decreases expression |
ISO |
bicalutamide results in decreased expression of GPRC5A mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 4:167,903,542...167,922,276
Ensembl chr 4:167,903,542...167,922,260
|
|
G |
Greb1 |
growth regulating estrogen receptor binding 1 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Testosterone results in increased expression of GREB1 mRNA] |
CTD |
PMID:16496412 |
|
NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633
|
|
G |
Gtpbp2 |
GTP binding protein 2 |
increases expression |
ISO |
bicalutamide results in increased expression of GTPBP2 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 9:14,813,964...14,823,419
Ensembl chr 9:14,813,964...14,823,241
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions |
EXP |
bicalutamide results in increased expression of HIF1A protein bicalutamide promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of HIF1A protein] |
CTD |
PMID:35151640 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk2 |
hexokinase 2 |
increases expression |
EXP |
bicalutamide results in increased expression of HK2 protein |
CTD |
PMID:35151640 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hyou1 |
hypoxia up-regulated 1 |
increases expression |
ISO |
bicalutamide results in increased expression of HYOU1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 8:44,706,073...44,718,189
Ensembl chr 8:44,706,263...44,718,186
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]] |
CTD |
PMID:16317058 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions increases expression |
ISO |
[bicalutamide co-treated with Tamoxifen] results in decreased expression of IGF1 protein; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of IGF1 mRNA] bicalutamide results in increased expression of IGF1 mRNA; bicalutamide results in increased expression of IGF1 protein |
CTD |
PMID:16368782 PMID:16847815 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions |
ISO |
[bicalutamide co-treated with Tamoxifen] results in increased expression of IGFBP1 protein |
CTD |
PMID:16847815 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
multiple interactions increases expression |
ISO EXP |
bicalutamide promotes the reaction [Dihydrotestosterone results in increased expression of IGFBP2 mRNA] bicalutamide results in increased expression of IGFBP2 mRNA |
CTD |
PMID:10604720 PMID:16368782 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions increases expression decreases secretion decreases expression |
ISO EXP |
[bicalutamide co-treated with Tamoxifen] results in increased expression of IGFBP3 protein bicalutamide results in increased expression of IGFBP3 protein bicalutamide results in increased expression of IGFBP3 mRNA bicalutamide results in decreased secretion of IGFBP3 protein bicalutamide results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:10604720 PMID:16368782 PMID:16847815 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
increases expression |
EXP |
bicalutamide results in increased expression of IGFBP4 mRNA |
CTD |
PMID:10604720 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
increases expression |
EXP |
bicalutamide results in increased expression of IGFBP5 mRNA |
CTD |
PMID:10604720 |
|
NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[IL6 protein results in increased expression of NCOA2 protein] which results in decreased susceptibility to bicalutamide; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [BCG Vaccine results in increased expression of IL6 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]]; bicalutamide inhibits the reaction [IL6 protein results in increased expression of KLK3 mRNA] |
CTD |
PMID:11410519 PMID:14532843 PMID:16317058 PMID:19240160 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kif20a |
kinesin family member 20A |
decreases expression |
ISO |
bicalutamide results in decreased expression of KIF20A mRNA |
CTD |
PMID:15638997 |
|
NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
increases expression |
ISO |
bicalutamide results in increased expression of LAMP2 mRNA |
CTD |
PMID:16631469 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Lamp3 |
lysosomal-associated membrane protein 3 |
increases expression |
ISO |
bicalutamide results in increased expression of LAMP3 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr11:81,153,491...81,224,643
Ensembl chr11:81,193,649...81,221,784
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
bicalutamide results in increased expression of LCN2 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldha |
lactate dehydrogenase A |
increases expression |
EXP |
bicalutamide results in increased expression of LDHA protein |
CTD |
PMID:35151640 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Ldlr |
low density lipoprotein receptor |
affects localization |
ISO |
bicalutamide affects the localization of LDLR protein |
CTD |
PMID:17440980 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lmnb1 |
lamin B1 |
decreases expression |
ISO |
bicalutamide results in decreased expression of LMNB1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502
|
|
G |
LOC102549061 |
histone H2B type 1-N-like |
increases expression |
ISO |
bicalutamide results in increased expression of H2BC3 mRNA |
CTD |
PMID:15790403 |
|
NCBI chr17:41,380,058...41,380,685
|
|
G |
Lrba |
LPS responsive beige-like anchor protein |
increases expression |
ISO |
bicalutamide results in increased expression of LRBA mRNA |
CTD |
PMID:15790403 |
|
NCBI chr 2:171,623,668...172,202,576
Ensembl chr 2:171,621,507...172,202,724
|
|
G |
Mad2l1 |
mitotic arrest deficient 2 like 1 |
decreases expression |
ISO |
bicalutamide results in decreased expression of MAD2L1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 4:95,906,692...95,918,885
Ensembl chr 4:95,906,817...95,913,470
|
|
G |
Man1a1 |
mannosidase, alpha, class 1A, member 1 |
increases expression |
ISO |
bicalutamide results in increased expression of MAN1A1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr20:33,202,509...33,385,747
Ensembl chr20:33,202,517...33,385,824
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [bicalutamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; bicalutamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein |
CTD |
PMID:15466214 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [bicalutamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; bicalutamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein |
CTD |
PMID:15466214 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [bicalutamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; bicalutamide inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased phosphorylation of and results in increased activity of MAPK1 protein]; bicalutamide results in increased phosphorylation of and results in increased activity of MAPK1 protein |
CTD |
PMID:15466214 PMID:29383186 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [bicalutamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; bicalutamide inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased phosphorylation of and results in increased activity of MAPK3 protein]; bicalutamide results in increased phosphorylation of and results in increased activity of MAPK3 protein |
CTD |
PMID:15466214 PMID:29383186 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mbd2 |
methyl-CpG binding domain protein 2 |
increases expression |
ISO |
bicalutamide results in increased expression of MBD2 mRNA |
CTD |
PMID:16631469 |
|
NCBI chr18:64,174,002...64,240,795
Ensembl chr18:64,174,002...64,240,794
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
decreases expression |
ISO |
bicalutamide results in decreased expression of MCM2 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847
|
|
G |
Mdk |
midkine |
increases expression |
ISO |
bicalutamide results in increased expression of MDK mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 3:77,901,156...77,903,997
Ensembl chr 3:77,901,158...77,903,130
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Testosterone results in increased expression of MET mRNA] |
CTD |
PMID:11139396 PMID:17371283 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mir21 |
microRNA 21 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dehydroepiandrosterone results in increased expression of MIR21 mRNA]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of MIR21 mRNA]; bicalutamide inhibits the reaction [fludioxonil results in increased expression of MIR21 mRNA]; bicalutamide inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR21 mRNA] |
CTD |
PMID:23052036 PMID:25969534 |
|
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
bicalutamide results in decreased expression of MKI67 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mme |
membrane metallo-endopeptidase |
increases expression |
ISO |
bicalutamide results in increased expression of MME mRNA |
CTD |
PMID:15790403 |
|
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Androgens results in increased expression of MMP13 mRNA] |
CTD |
PMID:15138554 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Metribolone results in increased expression of MMP2 mRNA] |
CTD |
PMID:16888681 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Msmb |
microseminoprotein, beta |
decreases expression |
ISO |
bicalutamide results in decreased expression of MSMB mRNA |
CTD |
PMID:33932781 |
|
NCBI chr16:7,366,536...7,387,124
Ensembl chr16:7,366,536...7,387,123
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions increases expression decreases expression |
ISO |
[Niclosamide co-treated with bicalutamide] results in decreased expression of MYC mRNA; [Niclosamide co-treated with bicalutamide] results in decreased expression of MYC protein; bicalutamide inhibits the reaction [Dihydrotestosterone promotes the reaction [AR protein binds to MYC enhancer]]; bicalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of MYC mRNA]; Niclosamide inhibits the reaction [bicalutamide results in increased expression of MYC protein] bicalutamide results in decreased expression of MYC mRNA |
CTD |
PMID:15638997 PMID:24759320 PMID:28500234 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myo6 |
myosin VI |
increases expression |
ISO |
bicalutamide results in increased expression of MYO6 mRNA |
CTD |
PMID:15790403 PMID:16631469 |
|
NCBI chr 8:81,087,157...81,242,022
Ensembl chr 8:81,087,139...81,239,292
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [AR protein binds to NCOA1 protein] |
CTD |
PMID:11981028 |
|
NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
[IL6 protein results in increased expression of NCOA2 protein] which results in decreased susceptibility to bicalutamide |
CTD |
PMID:19240160 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions |
ISO |
bicalutamide promotes the reaction [AR protein binds to NCOR2 protein] |
CTD |
PMID:11981028 |
|
NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319
|
|
G |
Nebl |
nebulette |
increases expression |
ISO |
bicalutamide results in increased expression of NEBL mRNA |
CTD |
PMID:15638997 |
|
NCBI chr17:80,113,891...80,466,331
Ensembl chr17:80,118,543...80,466,210
|
|
G |
Nek2 |
NIMA-related kinase 2 |
decreases expression |
ISO |
bicalutamide results in decreased expression of NEK2 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051
|
|
G |
Niban1 |
niban apoptosis regulator 1 |
increases expression |
ISO |
bicalutamide results in increased expression of NIBAN1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr13:63,674,240...63,827,748
Ensembl chr13:63,674,171...63,827,729
|
|
G |
Nkx3-1 |
NK3 homeobox 1 |
multiple interactions decreases expression |
ISO |
[Niclosamide co-treated with bicalutamide] results in decreased expression of NKX3-1 mRNA; bicalutamide inhibits the reaction [Antimony Potassium Tartrate results in increased expression of NKX3-1 mRNA]; bicalutamide inhibits the reaction [Cadmium Chloride results in increased expression of NKX3-1 mRNA]; bicalutamide inhibits the reaction [Metribolone results in increased expression of NKX3-1 mRNA] bicalutamide results in decreased expression of NKX3-1 mRNA |
CTD |
PMID:11751618 PMID:15638997 PMID:28500234 PMID:29462692 |
|
NCBI chr15:44,473,851...44,476,443
Ensembl chr15:44,473,851...44,476,441
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
bicalutamide binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nrp1 |
neuropilin 1 |
decreases expression |
ISO |
bicalutamide results in decreased expression of NRP1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
|
|
G |
Nts |
neurotensin |
decreases response to substance |
ISO |
NTS protein results in decreased susceptibility to bicalutamide |
CTD |
PMID:17044078 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Nusap1 |
nucleolar and spindle associated protein 1 |
decreases expression |
ISO |
bicalutamide results in decreased expression of NUSAP1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 3:106,603,273...106,633,624
Ensembl chr 3:106,603,289...106,633,624
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [OSM protein results in increased activity of AR protein] |
CTD |
PMID:12114440 |
|
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
|
|
G |
Pa2g4 |
proliferation-associated 2G4 |
multiple interactions increases response to substance |
ISO |
bicalutamide promotes the reaction [PA2G4 protein binds to KLK3 promoter] PA2G4 protein results in increased susceptibility to bicalutamide |
CTD |
PMID:15994225 |
|
NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
bicalutamide promotes the reaction [Niclosamide results in increased expression of PARP1 protein modified form] |
CTD |
PMID:28500234 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pbk |
PDZ binding kinase |
decreases expression |
ISO |
bicalutamide results in decreased expression of PBK mRNA |
CTD |
PMID:15638997 |
|
NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
ISO |
bicalutamide results in decreased expression of PCNA mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pds5b |
PDS5 cohesin associated factor B |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Calcitriol results in increased expression of APRIN] |
CTD |
PMID:15754350 |
|
NCBI chr12:202,481...345,596
Ensembl chr12:255,313...345,596
|
|
G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
increases expression |
ISO |
bicalutamide results in increased expression of PECR mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511
|
|
G |
Pfkm |
phosphofructokinase, muscle |
decreases expression |
EXP |
bicalutamide results in decreased expression of PFKM protein |
CTD |
PMID:35151640 |
|
NCBI chr 7:129,221,679...129,259,192
Ensembl chr 7:129,221,653...129,259,192
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
bicalutamide binds to and results in decreased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Phb1 |
prohibitin 1 |
multiple interactions |
ISO |
[Dihydrotestosterone co-treated with bicalutamide] promotes the reaction [AR protein binds to PHB1 protein]; AR protein promotes the reaction [bicalutamide promotes the reaction [PHB1 protein binds to KLK3 promoter]]; bicalutamide promotes the reaction [PHB1 protein binds to KLK3 promoter]; PHB1 protein promotes the reaction [bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]]; PHB1 protein promotes the reaction [bicalutamide promotes the reaction [SMARCA4 protein binds to KLK3 promoter]] |
CTD |
PMID:18487222 |
|
NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042
|
|
G |
Pip |
prolactin induced protein |
decreases expression multiple interactions |
ISO |
bicalutamide results in decreased expression of PIP mRNA bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of PIP mRNA] |
CTD |
PMID:10402478 |
|
NCBI chr 4:70,787,627...70,791,921
Ensembl chr 4:70,787,627...70,791,921
|
|
G |
Pklr |
pyruvate kinase L/R |
decreases expression |
EXP |
bicalutamide results in decreased expression of PKLR protein |
CTD |
PMID:35151640 |
|
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
bicalutamide binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
ISO |
bicalutamide results in decreased expression of PRC1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases activity |
ISO |
bicalutamide promotes the reaction [PTEN protein results in decreased expression of KLK3 mRNA] bicalutamide results in increased activity of PTEN protein |
CTD |
PMID:16637073 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]] |
CTD |
PMID:16317058 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Racgap1 |
Rac GTPase-activating protein 1 |
decreases expression |
ISO |
bicalutamide results in decreased expression of RACGAP1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831
|
|
G |
Ranbp1 |
RAN binding protein 1 |
decreases expression |
ISO |
bicalutamide results in decreased expression of RANBP1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr11:82,742,603...82,750,836
Ensembl chr11:82,742,600...82,750,838
|
|
G |
Rarb |
retinoic acid receptor, beta |
increases expression |
ISO |
bicalutamide results in increased expression of RARB mRNA |
CTD |
PMID:15790403 |
|
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
increases phosphorylation |
ISO |
bicalutamide results in increased phosphorylation of RB1 protein |
CTD |
PMID:17599054 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rom1 |
retinal outer segment membrane protein 1 |
increases expression |
ISO |
bicalutamide results in increased expression of ROM1 mRNA |
CTD |
PMID:15790403 |
|
NCBI chr 1:205,824,050...205,826,058
Ensembl chr 1:205,824,052...205,826,175
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions |
ISO |
[bicalutamide co-treated with Testosterone] results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:21036700 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[bicalutamide co-treated with Testosterone] results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:21036700 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
decreases expression |
ISO |
bicalutamide results in decreased expression of RRM2 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
Rxrb |
retinoid X receptor beta |
decreases expression |
ISO |
bicalutamide results in decreased expression of RXRB |
CTD |
PMID:11845989 |
|
NCBI chr20:4,816,813...4,823,267
Ensembl chr20:4,816,815...4,828,773
|
|
G |
Scgb2a1 |
secretoglobin, family 2A, member 1 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of SCGB2A1 mRNA] |
CTD |
PMID:16020486 |
|
NCBI chr 1:206,497,848...206,501,211
Ensembl chr 1:206,497,849...206,501,211 Ensembl chr 1:206,497,849...206,501,211
|
|
G |
Sem1 |
SEM1 26S proteasome subunit |
increases expression |
ISO |
bicalutamide results in increased expression of SEM1 mRNA |
CTD |
PMID:16631469 |
|
NCBI chr 4:34,671,848...34,692,005
Ensembl chr 4:34,671,848...34,692,005
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of SERPINE1 mRNA]] |
CTD |
PMID:16317058 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions increases expression decreases expression |
EXP |
bicalutamide promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of SLC2A1 protein] bicalutamide results in increased expression of SLC2A1 protein bicalutamide results in decreased expression of SLC2A1 protein |
CTD |
PMID:35151640 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
increases expression |
ISO |
bicalutamide results in increased expression of SLC3A2 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc4a4 |
solute carrier family 4 member 4 |
decreases expression |
ISO |
bicalutamide results in decreased expression of SLC4A4 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr14:18,841,289...19,293,297
Ensembl chr14:18,845,159...19,272,883
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
bicalutamide results in increased expression of SLC7A11 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Smarca4 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 |
multiple interactions |
ISO |
[Dihydrotestosterone co-treated with bicalutamide] promotes the reaction [AR protein binds to SMARCA4 protein]; bicalutamide promotes the reaction [SMARCA4 protein binds to KLK3 promoter]; PHB1 protein promotes the reaction [bicalutamide promotes the reaction [SMARCA4 protein binds to KLK3 promoter]] |
CTD |
PMID:18487222 |
|
NCBI chr 8:20,167,717...20,258,975
Ensembl chr 8:20,167,717...20,258,975
|
|
G |
Snap25 |
synaptosome associated protein 25 |
increases expression |
ISO |
bicalutamide results in increased expression of SNAP25 mRNA |
CTD |
PMID:15790403 |
|
NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
|
|
G |
Sord |
sorbitol dehydrogenase |
increases expression |
ISO |
bicalutamide results in increased expression of SORD mRNA |
CTD |
PMID:15790403 |
|
NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133
|
|
G |
Spint2 |
serine peptidase inhibitor, Kunitz type, 2 |
increases expression |
ISO |
bicalutamide results in increased expression of SPINT2 mRNA |
CTD |
PMID:15790403 |
|
NCBI chr 1:84,558,159...84,580,616
Ensembl chr 1:84,558,166...84,580,616
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
bicalutamide results in increased expression of SQSTM1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases expression |
ISO |
bicalutamide results in decreased expression of STIP1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 1:204,209,434...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G |
Tamm41 |
TAM41 mitochondrial translocator assembly and maintenance homolog |
increases expression |
ISO |
bicalutamide results in increased expression of TAMM41 mRNA |
CTD |
PMID:16631469 |
|
NCBI chr 4:148,070,388...148,103,728
Ensembl chr 4:148,018,463...148,103,694
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases activity decreases expression |
ISO |
bicalutamide results in decreased activity of TERT protein bicalutamide results in decreased expression of TERT mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
bicalutamide binds to and results in increased activity of THRA protein |
CTD |
PMID:33049310 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
bicalutamide binds to and results in increased activity of THRB protein |
CTD |
PMID:33049310 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Tk1 |
thymidine kinase 1 |
decreases expression |
ISO |
bicalutamide results in decreased expression of TK1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA]] |
CTD |
PMID:16317058 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tmeff2 |
transmembrane protein with EGF-like and two follistatin-like domains 2 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of TMEFF2 protein] |
CTD |
PMID:23405127 |
|
NCBI chr 9:50,445,550...50,733,482
Ensembl chr 9:50,436,079...50,733,475
|
|
G |
Tmsb4x |
thymosin beta 4, X-linked |
multiple interactions increases expression |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of TMSB4X mRNA] bicalutamide results in increased expression of TMSB4X mRNA |
CTD |
PMID:17916567 |
|
NCBI chr X:27,144,677...27,146,667
Ensembl chr X:27,128,610...27,146,667
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]] |
CTD |
PMID:16317058 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO |
bicalutamide results in increased expression of TP53 protein bicalutamide inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein] |
CTD |
PMID:15638997 PMID:29383186 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53i3 |
tumor protein p53 inducible protein 3 |
increases expression |
ISO |
bicalutamide results in increased expression of TP53I3 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 6:27,818,327...27,827,030
|
|
G |
Tpd52 |
tumor protein D52 |
decreases response to substance |
ISO |
TPD52 protein results in decreased susceptibility to bicalutamide |
CTD |
PMID:17875733 |
|
NCBI chr 2:92,735,246...92,816,079
Ensembl chr 2:92,735,620...92,816,622
|
|
G |
Tpx2 |
TPX2, microtubule nucleation factor |
decreases expression |
ISO |
bicalutamide results in decreased expression of TPX2 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 3:141,318,428...141,360,684
Ensembl chr 3:141,318,455...141,360,468
|
|
G |
Tram1 |
translocation associated membrane protein 1 |
increases expression |
ISO |
bicalutamide results in increased expression of TRAM1 mRNA |
CTD |
PMID:16631469 |
|
NCBI chr 5:5,642,579...5,667,666
Ensembl chr 5:5,642,546...5,686,971
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression |
ISO |
bicalutamide results in increased expression of TRIB3 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Tyms |
thymidylate synthetase |
decreases expression |
ISO |
bicalutamide results in decreased expression of TYMS protein |
CTD |
PMID:17599054 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Uap1 |
UDP-N-acetylglucosamine pyrophosphorylase 1 |
increases expression |
ISO |
bicalutamide results in increased expression of UAP1 mRNA |
CTD |
PMID:15790403 |
|
NCBI chr13:82,342,946...82,377,558
Ensembl chr13:82,342,946...82,377,469
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
multiple interactions |
ISO |
[Niclosamide co-treated with bicalutamide] results in decreased expression of UBE2C mRNA |
CTD |
PMID:28500234 |
|
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
|
|
G |
Ugt2b17 |
UDP glucuronosyltransferase family 2 member B17 |
decreases expression |
ISO |
bicalutamide results in decreased expression of UGT2B17 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
|
|
G |
Upp1 |
uridine phosphorylase 1 |
increases expression |
ISO |
bicalutamide results in increased expression of UPP1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr14:83,809,495...83,829,299
Ensembl chr14:83,809,960...83,829,462
|
|
G |
Uxt |
ubiquitously-expressed, prefoldin-like chaperone |
affects response to substance |
ISO |
UXT protein affects the susceptibility to bicalutamide |
CTD |
PMID:19318562 |
|
NCBI chr X:1,126,110...1,138,670
Ensembl chr X:1,126,162...1,138,663
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]] |
CTD |
PMID:16317058 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Wars1 |
tryptophanyl-tRNA synthetase 1 |
increases expression |
ISO |
bicalutamide results in increased expression of WARS1 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 6:127,776,088...127,807,273
Ensembl chr 6:127,776,090...127,807,269
|
|
G |
Ythdf3 |
YTH N(6)-methyladenosine RNA binding protein 3 |
increases expression |
ISO |
bicalutamide results in increased expression of YTHDF3 mRNA |
CTD |
PMID:16631469 |
|
NCBI chr 2:98,350,304...98,384,608
Ensembl chr 2:98,350,588...98,384,606
|
|
G |
Zmat3 |
zinc finger, matrin type 3 |
increases expression |
ISO |
bicalutamide results in increased expression of ZMAT3 mRNA |
CTD |
PMID:15638997 |
|
NCBI chr 2:115,106,050...115,136,863
Ensembl chr 2:115,106,966...115,136,863
|
|
G |
Zwint |
ZW10 interacting kinetochore protein |
decreases expression |
ISO |
bicalutamide results in decreased expression of ZWINT mRNA |
CTD |
PMID:15638997 |
|
NCBI chr20:15,938,157...15,953,997
Ensembl chr20:15,938,157...15,953,957
|
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases expression |
ISO |
bictegravir results in decreased expression of ALDH1A2 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
increases expression |
ISO |
bictegravir results in increased expression of CYP26A1 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
increases expression |
ISO |
bictegravir results in increased expression of FGF8 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 1:244,584,477...244,590,359
Ensembl chr 1:244,584,652...244,590,359
|
|
G |
Mixl1 |
Mix paired-like homeobox 1 |
increases expression |
ISO |
bictegravir results in increased expression of MIXL1 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr13:92,422,031...92,426,065
Ensembl chr13:92,422,031...92,426,065
|
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein |
CTD |
PMID:33728909 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
|
G |
Dhodh |
dihydroorotate dehydrogenase (quinone) |
multiple interactions decreases activity |
EXP ISO |
brequinar inhibits the reaction [DHODH protein results in increased metabolism of 4,5-dihydroorotic acid]; brequinar inhibits the reaction [DHODH protein results in increased metabolism of Quinones]; brequinar inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid] brequinar results in decreased activity of DHODH protein |
CTD |
PMID:9776318 PMID:9802339 PMID:10658902 |
|
NCBI chr19:37,551,858...37,573,327
Ensembl chr19:37,558,177...37,591,654
|
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression multiple interactions |
ISO |
cobimetinib results in increased expression of BCL2L11 protein; cobimetinib results in increased expression of BCL2L11 protein alternative form 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in increased expression of BCL2L11 protein alternative form]; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in increased expression of BCL2L11 protein]; [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with cobimetinib] results in decreased phosphorylation of BCL2L11 protein alternative form; cobimetinib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased expression of BCL2L11 protein alternative form] |
CTD |
PMID:22084396 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
multiple interactions increases response to substance |
ISO |
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [BRAF protein mutant form results in increased susceptibility to cobimetinib] |
CTD |
PMID:22084396 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
cobimetinib results in decreased expression of CCND1 protein 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in decreased expression of CCND1 protein] |
CTD |
PMID:22084396 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases secretion |
EXP |
cobimetinib results in increased secretion of GPT protein |
CTD |
PMID:29655783 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
increases response to substance multiple interactions |
ISO |
KRAS protein mutant form results in increased susceptibility to cobimetinib 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [KRAS protein mutant form results in increased susceptibility to cobimetinib]; cobimetinib promotes the reaction [KRAS protein mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] |
CTD |
PMID:22084396 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
ISO |
cobimetinib results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:22084396 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation |
ISO |
cobimetinib results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:22084396 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nras |
NRAS proto-oncogene, GTPase |
increases response to substance |
ISO |
NRAS protein mutant form results in increased susceptibility to cobimetinib |
CTD |
PMID:22084396 |
|
NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in increased cleavage of PARP1 protein]; cobimetinib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased cleavage of PARP1 protein] |
CTD |
PMID:22084396 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions |
ISO |
cobimetinib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in decreased phosphorylation of RPS6 protein] |
CTD |
PMID:22084396 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions affects metabolic processing |
ISO |
Quinidine affects the reaction [CYP2D6 protein polymorphism affects the metabolism of dacomitinib] |
CTD |
PMID:34936353 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
dacomitinib inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:27491023 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one promotes the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]] |
CTD |
PMID:31348943 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one promotes the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of AKT1 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:31348943 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Tunicamycin results in increased secretion of APP protein modified form] |
CTD |
PMID:22115781 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of BAX protein |
CTD |
PMID:21209419 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of BCL2 protein |
CTD |
PMID:21209419 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT10 mRNA] |
CTD |
PMID:23566955 |
|
NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of and results in increased activity of CASP3 protein |
CTD |
PMID:21209419 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of CCND1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of CCND1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester co-treated with 1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one] inhibits the reaction [polyhexamethyleneguanidine results in decreased expression of CDH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased secretion of CDH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium results in increased cleavage of CDH1 protein] |
CTD |
PMID:18791180 PMID:31348943 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased cleavage of CDH2 protein] |
CTD |
PMID:23876460 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of CSF1 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of ENO2 mRNA] |
CTD |
PMID:24929042 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of FLT1 protein] |
CTD |
PMID:21843347 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Hydrogen Peroxide results in increased expression of FOXO3 protein] |
CTD |
PMID:25108166 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions decreases expression |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Hydrogen Peroxide results in increased expression of HES1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of HES1 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of HES1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of HES1 protein |
CTD |
PMID:19160421 PMID:24223152 PMID:25005833 PMID:25108166 PMID:32041402 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr 2:93,096,706...93,100,316
Ensembl chr 2:93,095,498...93,100,312
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY2 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY2 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Niclosamide results in increased expression of HEY2 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of HEY2 mRNA] |
CTD |
PMID:19160421 PMID:32041402 |
|
NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Hydrogen Peroxide results in increased expression of HIF1A protein] |
CTD |
PMID:25108166 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of HMGB1 protein] |
CTD |
PMID:21843347 |
|
NCBI chr12:5,973,062...5,978,565
Ensembl chr12:5,901,586...5,978,565
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL10 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL1B protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL1B mRNA] |
CTD |
PMID:21843347 PMID:24223152 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL6 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein] |
CTD |
PMID:21843347 PMID:24223152 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of ITGAM protein] |
CTD |
PMID:28130038 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Ivl |
involucrin |
decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of IVL mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of IVL protein |
CTD |
PMID:18633435 |
|
NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of JAG1 mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of JAG1 protein |
CTD |
PMID:18633435 |
|
NCBI chr 3:124,406,794...124,442,220
Ensembl chr 3:124,406,794...124,442,209
|
|
G |
Krt1 |
keratin 1 |
multiple interactions decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [U 0126 results in increased expression of KRT1 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT1 mRNA |
CTD |
PMID:18633435 PMID:23566955 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Krt10 |
keratin 10 |
multiple interactions decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT10 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [U 0126 results in increased expression of KRT10 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT10 mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT10 protein |
CTD |
PMID:18633435 PMID:23566955 |
|
NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701
|
|
G |
Lgr5 |
leucine rich repeat containing G protein coupled receptor 5 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of LGR5 mRNA] |
CTD |
PMID:32041402 |
|
NCBI chr 7:51,087,059...51,221,882
Ensembl chr 7:51,088,239...51,222,446
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of MAP2 mRNA] |
CTD |
PMID:24929042 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions increases expression |
ISO |
Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of MDM2 protein] |
CTD |
PMID:25005833 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of MYD88 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of MYD88 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of NOS2 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of NOS2 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch1 |
notch receptor 1 |
multiple interactions decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Hydrogen Peroxide results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [phenethyl isothiocyanate results in increased cleavage of and results in increased activity of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [polyhexamethyleneguanidine results in increased cleavage of NOTCH1 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased cleavage of and results in decreased activity of NOTCH1 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency affects the localization of NOTCH1 protein modified form]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Tunicamycin results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Oxygen deficiency results in increased expression of NOTCH1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH1 protein modified form |
CTD |
PMID:18633435 PMID:22039516 PMID:22115781 PMID:24223152 PMID:25108166 PMID:25118938 PMID:28130038 PMID:31348943 More...
|
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Notch2 |
notch receptor 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased cleavage of and results in decreased activity of NOTCH2 protein |
CTD |
PMID:22039516 |
|
NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088
|
|
G |
Numb |
NUMB, endocytic adaptor protein |
increases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of NUMB protein |
CTD |
PMID:25005833 |
|
NCBI chr 6:103,431,400...103,553,422
Ensembl chr 6:103,431,400...103,553,354
|
|
G |
Pml |
PML nuclear body scaffold |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]] |
CTD |
PMID:28130038 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium results in increased expression of PTGS2 mRNA] |
CTD |
PMID:18791180 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]] |
CTD |
PMID:28130038 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
multiple interactions increases expression |
EXP ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of RBPJ mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of RBPJ protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cycloheximide results in decreased expression of RBPJ protein] |
CTD |
PMID:22302987 PMID:24223152 |
|
NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency affects the localization of RELA protein modified form]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of RELA protein] |
CTD |
PMID:24223152 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TGFB1 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TLR4 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TNF protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TNF mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein] |
CTD |
PMID:25005833 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TRAF6 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TRAF6 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of TUBB3 mRNA] |
CTD |
PMID:24929042 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein] |
CTD |
PMID:21843347 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vil1 |
villin 1 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of VIL1 mRNA] |
CTD |
PMID:32041402 |
|
NCBI chr 9:75,991,141...76,018,860
Ensembl chr 9:75,991,141...76,018,858
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects binding |
ISO |
difloxacin binds to KCNH2 protein |
CTD |
PMID:34058295 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
EXP |
Diflubenzuron results in increased expression of CYP1A1 protein |
CTD |
PMID:8812189 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects binding |
ISO |
Diflubenzuron binds to CYP1A2 protein |
CTD |
PMID:32278787 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects binding |
ISO |
Diflubenzuron binds to CYP3A4 protein |
CTD |
PMID:32278787 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression |
EXP |
Diflubenzuron results in increased expression of CYP3A23-3A1 protein |
CTD |
PMID:8812189 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
Diflubenzuron results in increased activity of NR1I2 protein |
CTD |
PMID:16565514 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Diflunisal results in increased expression of FOS mRNA |
CTD |
PMID:12730611 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
EXP |
Diflunisal results in increased expression of IL1B mRNA |
CTD |
PMID:15135310 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression |
EXP |
Diflunisal results in increased expression of IL6 mRNA |
CTD |
PMID:15135310 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
EXP |
Diflunisal results in increased expression of NOS2 mRNA |
CTD |
PMID:15135310 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Slc6a8 |
solute carrier family 6 member 8 |
increases expression |
ISO |
Diflunisal results in increased expression of SLC6A8 mRNA |
CTD |
PMID:29901742 |
|
NCBI chr X:151,384,675...151,393,979
Ensembl chr X:151,384,675...151,393,979
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
Diflunisal results in increased expression of TNF mRNA |
CTD |
PMID:15135310 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ttr |
transthyretin |
affects binding multiple interactions |
ISO |
Diflunisal binds to TTR protein mutant form [Diflunisal binds to TTR protein mutant form] which results in decreased susceptibility to Urea; Diflunisal results in increased stability of [TTR protein binds to TTR protein binds to TTR protein binds to TTR protein] |
CTD |
PMID:17701470 PMID:27093678 |
|
NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
decreases activity |
ISO |
Diflunisal results in decreased activity of UGT1A1 protein |
CTD |
PMID:15593333 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of Diflunisal |
CTD |
PMID:15117964 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
multiple interactions increases glucuronidation |
ISO |
Diflunisal inhibits the reaction [UGT2B7 protein results in increased chemical synthesis of aldosterone 18-glucuronide]; Diflunisal inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone] UGT2B7 protein alternative form results in increased glucuronidation of Diflunisal; UGT2B7 protein results in increased glucuronidation of Diflunisal |
CTD |
PMID:8423545 PMID:8517101 PMID:19740398 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases expression |
ISO |
dolutegravir results in decreased expression of ALDH1A2 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Cdx1 |
caudal type homeo box 1 |
decreases expression |
ISO |
dolutegravir results in decreased expression of CDX1 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr18:54,472,448...54,499,799
Ensembl chr18:54,473,444...54,490,814
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
decreases expression increases expression |
ISO |
dolutegravir results in decreased expression of CYP26A1 mRNA dolutegravir results in increased expression of CYP26A1 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
increases expression |
ISO |
dolutegravir results in increased expression of FGF8 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 1:244,584,477...244,590,359
Ensembl chr 1:244,584,652...244,590,359
|
|
G |
Hoxb1 |
homeo box B1 |
increases expression |
ISO |
dolutegravir results in increased expression of HOXB1 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr10:81,331,507...81,332,928
Ensembl chr10:81,331,507...81,332,836
|
|
G |
Hoxb9 |
homeo box B9 |
decreases expression |
ISO |
dolutegravir results in decreased expression of HOXB9 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr10:81,237,312...81,240,818
Ensembl chr10:81,237,312...81,240,818
|
|
G |
Meox1 |
mesenchyme homeobox 1 |
decreases expression |
ISO |
dolutegravir results in decreased expression of MEOX1 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr10:86,818,450...86,837,563
Ensembl chr10:86,818,478...86,837,660
|
|
G |
Mesp2 |
mesoderm posterior bHLH transcription factor 2 |
increases expression |
ISO |
dolutegravir results in increased expression of MESP2 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 1:133,756,601...133,759,207
Ensembl chr 1:133,756,601...133,759,198
|
|
G |
Mixl1 |
Mix paired-like homeobox 1 |
increases expression |
ISO |
dolutegravir results in increased expression of MIXL1 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr13:92,422,031...92,426,065
Ensembl chr13:92,422,031...92,426,065
|
|
G |
Tbx6 |
T-box transcription factor 6 |
increases expression |
ISO |
dolutegravir results in increased expression of TBX6 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 1:181,387,851...181,392,762
Ensembl chr 1:181,388,684...181,392,593
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
ISO |
eliprodil inhibits the reaction [KCNH2 protein results in increased transport of Thallium] |
CTD |
PMID:19583963 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
|
G |
Aadat |
aminoadipate aminotransferase |
decreases expression |
ISO |
enzalutamide results in decreased expression of AADAT mRNA |
CTD |
PMID:29581250 |
|
NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
decreases expression |
ISO |
enzalutamide results in decreased expression of ABCC4 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Acsm1 |
acyl-CoA synthetase medium-chain family member 1 |
decreases expression |
ISO |
enzalutamide results in decreased expression of ACSM1 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 1:173,985,715...174,020,565
Ensembl chr 1:173,984,672...174,025,495
|
|
G |
Adam10 |
ADAM metallopeptidase domain 10 |
affects expression |
ISO |
enzalutamide affects the expression of ADAM10 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
affects expression |
ISO |
enzalutamide affects the expression of ADAM17 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adprm |
ADP-ribose/CDP-alcohol diphosphatase, manganese-dependent |
decreases expression |
ISO |
enzalutamide results in decreased expression of ADPRM mRNA |
CTD |
PMID:29581250 |
|
NCBI chr10:51,732,073...51,744,635
Ensembl chr10:51,731,993...51,744,635
|
|
G |
Aff3 |
AF4/FMR2 family, member 3 |
decreases expression |
ISO |
enzalutamide results in decreased expression of AFF3 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 9:40,399,109...40,856,716
Ensembl chr 9:40,404,375...40,857,247
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
decreases expression |
ISO |
enzalutamide results in decreased expression of ALDH1A3 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Alpk2 |
alpha-kinase 2 |
decreases expression |
ISO |
enzalutamide results in decreased expression of ALPK2 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr18:58,775,603...58,906,150
Ensembl chr18:58,775,605...58,906,258
|
|
G |
Anxa4 |
annexin A4 |
affects expression |
ISO |
enzalutamide affects the expression of ANXA4 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Aph1a |
aph-1 homolog A, gamma secretase subunit |
affects expression |
ISO |
enzalutamide affects the expression of APH1A mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 2:183,437,676...183,443,113
Ensembl chr 2:183,438,434...183,441,955
|
|
G |
Aph1b |
aph-1 homolog B, gamma secretase subunit |
affects expression |
ISO |
enzalutamide affects the expression of APH1B mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 8:67,429,198...67,454,735
Ensembl chr 8:67,429,198...67,450,243
|
|
G |
App |
amyloid beta precursor protein |
affects expression |
ISO |
enzalutamide affects the expression of APP mRNA |
CTD |
PMID:30940724 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases activity decreases response to substance decreases expression |
ISO |
[enzalutamide co-treated with GSK-2816126] inhibits the reaction [AR protein binds to [EZH2 protein binds to SUZ12 protein binds to EED protein]]; [enzalutamide co-treated with Niclosamide] results in decreased expression of AR protein; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of AR mRNA; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of AR mRNA alternative form; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of AR protein; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of AR protein alternative form; [nirogacestat results in increased susceptibility to enzalutamide] which results in decreased expression of AR protein; enzalutamide binds to and results in decreased localization of and results in decreased activity of AR protein; enzalutamide inhibits the reaction [Dihydrotestosterone affects the localization of AR protein]; enzalutamide inhibits the reaction [Dihydrotestosterone promotes the reaction [AR protein binds to MYC enhancer]]; enzalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; Niclosamide inhibits the reaction [AR protein alternative form results in decreased susceptibility to enzalutamide] enzalutamide results in decreased activity of AR protein AR alternative form results in decreased susceptibility to enzalutamide; AR protein alternative form results in decreased susceptibility to enzalutamide; AR protein results in decreased susceptibility to enzalutamide enzalutamide results in decreased expression of AR protein; enzalutamide results in decreased expression of AR protein alternative form |
CTD |
PMID:19359544 PMID:24740322 PMID:24759320 PMID:25908785 PMID:25970160 PMID:28757136 PMID:30940724 PMID:32184358 PMID:32805266 More...
|
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Azgp1 |
alpha-2-glycoprotein 1, zinc-binding |
decreases expression |
ISO |
enzalutamide results in decreased expression of AZGP1 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr12:16,930,990...16,939,333
Ensembl chr12:16,931,024...16,939,091
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
enzalutamide promotes the reaction [Niclosamide results in decreased expression of BIRC5 protein] |
CTD |
PMID:25970160 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmpr1b |
bone morphogenetic protein receptor type 1B |
decreases expression |
ISO |
enzalutamide results in decreased expression of BMPR1B mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 2:230,538,252...230,871,077
Ensembl chr 2:230,541,558...230,871,368
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases expression |
ISO |
enzalutamide promotes the reaction [NVP-BHG712 results in increased cleavage of CASP3 protein] enzalutamide results in decreased expression of CASP3 protein |
CTD |
PMID:32184358 PMID:32805266 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
enzalutamide results in decreased expression of CASP8 protein |
CTD |
PMID:32805266 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
enzalutamide results in decreased expression of CCNB1 protein |
CTD |
PMID:32805266 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cd46 |
CD46 molecule |
increases expression |
ISO |
enzalutamide results in increased expression of CD46 protein |
CTD |
PMID:30185663 |
|
NCBI chr13:106,575,586...106,606,325
Ensembl chr13:106,574,858...106,660,445
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions |
ISO |
[enzalutamide co-treated with NVP-BHG712] results in decreased expression of CDC25C mRNA; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of CDC25C protein |
CTD |
PMID:32184358 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
affects expression |
ISO |
enzalutamide affects the expression of CDKN1B mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
affects expression |
ISO |
enzalutamide affects the expression of CEBPA mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Crebbp |
CREB binding protein |
affects expression |
ISO |
enzalutamide affects the expression of CREBBP mRNA |
CTD |
PMID:30940724 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crisp3 |
cysteine-rich secretory protein 3 |
decreases expression |
ISO |
enzalutamide results in decreased expression of CRISP3 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 9:20,432,051...20,472,663
Ensembl chr 9:20,450,908...20,472,658
|
|
G |
Crym |
crystallin, mu |
multiple interactions decreases expression |
ISO |
KDM1A protein promotes the reaction [enzalutamide results in decreased expression of CRYM mRNA] |
CTD |
PMID:29581250 |
|
NCBI chr 1:174,560,423...174,575,660
Ensembl chr 1:174,560,416...174,575,633
|
|
G |
Csgalnact1 |
chondroitin sulfate N-acetylgalactosaminyltransferase 1 |
decreases expression |
ISO |
enzalutamide results in decreased expression of CSGALNACT1 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr16:20,995,210...21,330,586
Ensembl chr16:21,235,784...21,330,319
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
decreases expression |
ISO |
enzalutamide results in decreased expression of DPP4 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 3:46,962,243...47,043,870
Ensembl chr 3:46,962,243...47,043,901
|
|
G |
Dtx2 |
deltex E3 ubiquitin ligase 2 |
affects expression |
ISO |
enzalutamide affects the expression of DTX2 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr12:20,643,289...20,682,908
Ensembl chr12:20,643,297...20,682,885
|
|
G |
Dtx3 |
deltex E3 ubiquitin ligase 3 |
affects expression |
ISO |
enzalutamide affects the expression of DTX3 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 7:63,013,769...63,018,431
Ensembl chr 7:63,013,371...63,018,522
|
|
G |
Dtx4 |
deltex E3 ubiquitin ligase 4 |
affects expression |
ISO |
enzalutamide affects the expression of DTX4 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 1:209,457,719...209,545,163
Ensembl chr 1:209,460,735...209,492,818
|
|
G |
Edem3 |
ER degradation enhancing alpha-mannosidase like protein 3 |
decreases expression |
ISO |
enzalutamide results in decreased expression of EDEM3 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr13:63,858,282...63,920,538
Ensembl chr13:63,858,716...63,920,523
|
|
G |
Eed |
embryonic ectoderm development |
multiple interactions decreases expression |
ISO |
[enzalutamide co-treated with GSK-2816126] inhibits the reaction [AR protein binds to [EZH2 protein binds to SUZ12 protein binds to EED protein]]; enzalutamide promotes the reaction [GSK-2816126 results in decreased expression of EED protein]; GSK-2816126 promotes the reaction [enzalutamide results in decreased expression of EED protein] |
CTD |
PMID:32805266 |
|
NCBI chr 1:143,867,875...143,895,008
Ensembl chr 1:143,867,875...143,894,974
|
|
G |
Efcab12 |
EF-hand calcium binding domain 12 |
decreases expression |
ISO |
enzalutamide results in decreased expression of EFCAB12 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 4:148,869,381...148,892,922
Ensembl chr 4:148,869,387...148,890,560
|
|
G |
Ell2 |
elongation factor for RNA polymerase II 2 |
decreases expression |
ISO |
enzalutamide results in decreased expression of ELL2 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 2:5,189,375...5,258,781
Ensembl chr 2:5,189,971...5,258,781
|
|
G |
Elovl7 |
ELOVL fatty acid elongase 7 |
decreases expression |
ISO |
enzalutamide results in decreased expression of ELOVL7 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 2:39,789,229...39,858,579
Ensembl chr 2:39,789,250...39,856,845
|
|
G |
Ep300 |
E1A binding protein p300 |
affects expression |
ISO |
enzalutamide affects the expression of EP300 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Ephb4 |
EPH receptor B4 |
affects response to substance multiple interactions |
ISO |
EPHB4 protein affects the susceptibility to enzalutamide enzalutamide promotes the reaction [EPHB4 protein affects the expression of KLK3 protein]; EPHB4 protein affects the reaction [enzalutamide results in decreased cleavage of PARP1 protein] |
CTD |
PMID:32184358 |
|
NCBI chr12:19,326,411...19,351,667
Ensembl chr12:19,326,427...19,351,314
|
|
G |
Epn1 |
Epsin 1 |
affects expression |
ISO |
enzalutamide affects the expression of EPN1 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 1:68,742,491...68,760,507
Ensembl chr 1:68,742,789...68,758,874
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
decreases expression multiple interactions |
ISO |
enzalutamide results in decreased expression of EZH2 protein [enzalutamide co-treated with GSK-2816126] inhibits the reaction [AR protein binds to [EZH2 protein binds to SUZ12 protein binds to EED protein]] |
CTD |
PMID:32805266 |
|
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions decreases expression |
ISO |
[enzalutamide co-treated with NVP-BHG712] results in decreased expression of FKBP5 mRNA; enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of FKBP5 mRNA]; NVP-BHG712 promotes the reaction [enzalutamide results in decreased expression of FKBP5 mRNA] |
CTD |
PMID:32184358 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Foxa1 |
forkhead box A1 |
affects expression |
ISO |
enzalutamide affects the expression of FOXA1 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188
|
|
G |
Galnt11 |
polypeptide N-acetylgalactosaminyltransferase 11 |
affects expression |
ISO |
enzalutamide affects the expression of GALNT11 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 4:9,837,629...9,871,141
Ensembl chr 4:9,837,629...9,871,140
|
|
G |
Gmds |
GDP-mannose 4, 6-dehydratase |
affects expression |
ISO |
enzalutamide affects the expression of GMDS mRNA |
CTD |
PMID:30940724 |
|
NCBI chr17:32,095,315...32,621,975
Ensembl chr17:32,095,386...32,621,961
|
|
G |
Gnmt |
glycine N-methyltransferase |
decreases expression |
ISO |
enzalutamide results in decreased expression of GNMT mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 9:14,254,675...14,258,028
Ensembl chr 9:14,254,675...14,258,434
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
affects expression |
ISO |
enzalutamide affects the expression of GOT1 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Greb1 |
growth regulating estrogen receptor binding 1 |
decreases expression |
ISO |
enzalutamide results in decreased expression of GREB1 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
affects expression |
ISO |
enzalutamide affects the expression of HES1 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hnf1b |
HNF1 homeobox B |
affects expression |
ISO |
enzalutamide affects the expression of HNF1B mRNA |
CTD |
PMID:30940724 |
|
NCBI chr10:68,735,894...68,789,888
Ensembl chr10:68,735,894...68,789,888
|
|
G |
Ift172 |
intraflagellar transport 172 |
affects expression |
ISO |
enzalutamide affects the expression of IFT172 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 6:25,081,933...25,121,271
Ensembl chr 6:25,081,980...25,120,860
|
|
G |
Ift74 |
intraflagellar transport 74 |
affects expression |
ISO |
enzalutamide affects the expression of IFT74 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 5:109,460,372...109,563,839
Ensembl chr 5:109,474,255...109,563,833
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases expression |
ISO |
enzalutamide results in decreased expression of IGF1 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
decreases expression |
ISO |
enzalutamide results in decreased expression of IGF1R mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases response to substance |
ISO |
Niclosamide inhibits the reaction [IL6 protein results in decreased susceptibility to enzalutamide] |
CTD |
PMID:25970160 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Iqgap2 |
IQ motif containing GTPase activating protein 2 |
decreases expression |
ISO |
enzalutamide results in decreased expression of IQGAP2 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 2:26,894,836...27,170,270
Ensembl chr 2:26,894,825...27,170,279
|
|
G |
Itch |
itchy E3 ubiquitin protein ligase |
affects expression |
ISO |
enzalutamide affects the expression of ITCH mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 3:143,642,348...143,733,745
Ensembl chr 3:143,645,637...143,733,543
|
|
G |
Itgb1bp1 |
integrin subunit beta 1 binding protein 1 |
affects expression |
ISO |
enzalutamide affects the expression of ITGB1BP1 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 6:40,820,693...40,836,074
Ensembl chr 6:40,821,339...40,836,037
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
affects expression |
ISO |
enzalutamide affects the expression of JAG1 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 3:124,406,794...124,442,220
Ensembl chr 3:124,406,794...124,442,209
|
|
G |
Jag2 |
jagged canonical Notch ligand 2 |
affects expression |
ISO |
enzalutamide affects the expression of JAG2 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 6:131,983,056...132,005,359
Ensembl chr 6:131,983,056...132,005,818
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
affects expression |
ISO |
enzalutamide affects the expression of KAT2B mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
|
|
G |
Kdm1a |
lysine demethylase 1A |
multiple interactions |
ISO |
KDM1A protein promotes the reaction [enzalutamide results in decreased expression of CRYM mRNA]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of KLK3 protein]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of LCP1 mRNA]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of MAP2 mRNA]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of MYO1B mRNA]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of SLC22A3 mRNA]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of TMCC3 mRNA] |
CTD |
PMID:29581250 |
|
NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319
|
|
G |
Kif5c |
kinesin family member 5C |
decreases expression |
ISO |
enzalutamide results in decreased expression of KIF5C mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413
|
|
G |
Krt19 |
keratin 19 |
affects expression |
ISO |
enzalutamide affects the expression of KRT19 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
decreases expression |
ISO |
enzalutamide results in decreased expression of LCK mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 5:141,888,319...141,916,992
Ensembl chr 5:141,888,326...141,903,794
|
|
G |
Lcp1 |
lymphocyte cytosolic protein 1 |
multiple interactions decreases expression |
ISO |
KDM1A protein promotes the reaction [enzalutamide results in decreased expression of LCP1 mRNA] |
CTD |
PMID:29581250 |
|
NCBI chr15:50,443,300...50,544,682
Ensembl chr15:50,488,149...50,544,680
|
|
G |
LOC498222 |
similar to specifically androgen-regulated protein |
decreases expression |
ISO |
enzalutamide results in decreased expression of C1ORF116 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr13:42,187,442...42,201,432
Ensembl chr13:42,188,609...42,201,426
|
|
G |
Maf |
MAF bZIP transcription factor |
decreases expression |
ISO |
enzalutamide results in decreased expression of MAF mRNA |
CTD |
PMID:29581250 |
|
NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365
|
|
G |
Maml1 |
mastermind-like transcriptional coactivator 1 |
affects expression |
ISO |
enzalutamide affects the expression of MAML1 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr10:34,588,639...34,624,298
Ensembl chr10:34,588,646...34,623,338
|
|
G |
Maml3 |
mastermind-like transcriptional coactivator 3 |
affects expression |
ISO |
enzalutamide affects the expression of MAML3 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 2:135,722,585...136,136,975
Ensembl chr 2:135,721,021...136,137,814
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
[enzalutamide co-treated with GSK-2816126] results in increased expression of MAP1LC3B protein modified form |
CTD |
PMID:32805266 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions decreases expression |
ISO |
KDM1A protein promotes the reaction [enzalutamide results in decreased expression of MAP2 mRNA] |
CTD |
PMID:29581250 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mdk |
midkine |
affects expression |
ISO |
enzalutamide affects the expression of MDK mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 3:77,901,156...77,903,997
Ensembl chr 3:77,901,158...77,903,130
|
|
G |
Mib1 |
MIB E3 ubiquitin protein ligase 1 |
affects expression |
ISO |
enzalutamide affects the expression of MIB1 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr18:1,802,519...1,926,988
Ensembl chr18:1,802,519...1,920,689
|
|
G |
Mib2 |
MIB E3 ubiquitin protein ligase 2 |
affects expression |
ISO |
enzalutamide affects the expression of MIB2 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 5:166,243,776...166,259,944
Ensembl chr 5:166,243,776...166,259,650
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of MKI67 protein] |
CTD |
PMID:32184358 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mpc2 |
mitochondrial pyruvate carrier 2 |
decreases expression |
ISO |
enzalutamide results in decreased expression of BRP44 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr13:77,728,176...77,747,664
Ensembl chr13:77,728,250...77,747,664
|
|
G |
Msmb |
microseminoprotein, beta |
decreases expression |
ISO |
enzalutamide results in decreased expression of MSMB mRNA |
CTD |
PMID:33932781 |
|
NCBI chr16:7,366,536...7,387,124
Ensembl chr16:7,366,536...7,387,123
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression multiple interactions affects expression |
ISO |
enzalutamide results in decreased expression of MYC protein [enzalutamide co-treated with NVP-BHG712] results in decreased expression of MYC protein; enzalutamide inhibits the reaction [Dihydrotestosterone promotes the reaction [AR protein binds to MYC enhancer]]; enzalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of MYC mRNA]; enzalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of MYC protein]; enzalutamide promotes the reaction [Niclosamide results in decreased expression of MYC protein]; enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of MYC protein] enzalutamide affects the expression of MYC mRNA |
CTD |
PMID:24759320 PMID:25970160 PMID:30940724 PMID:32184358 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myo1b |
myosin Ib |
multiple interactions decreases expression |
ISO |
KDM1A protein promotes the reaction [enzalutamide results in decreased expression of MYO1B mRNA] |
CTD |
PMID:29581250 |
|
NCBI chr 9:49,690,043...49,852,373
Ensembl chr 9:49,690,086...49,850,798
|
|
G |
Ncstn |
nicastrin |
affects expression |
ISO |
enzalutamide affects the expression of NCSTN mRNA |
CTD |
PMID:30940724 |
|
NCBI chr13:84,530,442...84,546,454
Ensembl chr13:84,530,440...84,546,454
|
|
G |
Neurl1b |
neuralized E3 ubiquitin protein ligase 1B |
affects expression |
ISO |
enzalutamide affects the expression of NEURL1B mRNA |
CTD |
PMID:30940724 |
|
NCBI chr10:16,758,097...16,784,943
Ensembl chr10:16,757,208...16,785,119
|
|
G |
Nkap |
NFKB activating protein |
affects expression |
ISO |
enzalutamide affects the expression of NKAP mRNA |
CTD |
PMID:30940724 |
|
NCBI chr X:116,373,031...116,392,677
Ensembl chr X:116,372,839...116,394,945
|
|
G |
Nkx3-1 |
NK3 homeobox 1 |
decreases expression multiple interactions |
ISO |
enzalutamide results in decreased expression of NKX3-1 mRNA enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of NKX3-1 mRNA]; NVP-BHG712 promotes the reaction [enzalutamide results in decreased expression of NKX3-1 mRNA] |
CTD |
PMID:29581250 PMID:32184358 |
|
NCBI chr15:44,473,851...44,476,443
Ensembl chr15:44,473,851...44,476,441
|
|
G |
Nle1 |
notchless homolog 1 |
affects expression |
ISO |
enzalutamide affects the expression of NLE1 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr10:67,834,059...67,844,771
Ensembl chr10:67,834,062...67,842,658
|
|
G |
Notch1 |
notch receptor 1 |
affects response to substance affects expression multiple interactions |
ISO |
NOTCH1 protein affects the susceptibility to enzalutamide enzalutamide affects the expression of NOTCH1 mRNA [NOTCH1 protein affects the susceptibility to enzalutamide] which affects the cleavage of PARP1 protein |
CTD |
PMID:30940724 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Notch2 |
notch receptor 2 |
affects expression |
ISO |
enzalutamide affects the expression of NOTCH2 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088
|
|
G |
Notch3 |
notch receptor 3 |
affects expression |
ISO |
enzalutamide affects the expression of NOTCH3 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
decreases cleavage multiple interactions |
ISO |
enzalutamide results in decreased cleavage of PARP1 protein [enzalutamide co-treated with GSK-2816126] results in increased cleavage of PARP1 protein; [nirogacestat results in increased susceptibility to enzalutamide] which results in increased cleavage of PARP1 protein; [NOTCH1 protein affects the susceptibility to enzalutamide] which affects the cleavage of PARP1 protein; enzalutamide promotes the reaction [NVP-BHG712 results in increased cleavage of PARP1 protein]; EPHB4 protein affects the reaction [enzalutamide results in decreased cleavage of PARP1 protein] |
CTD |
PMID:30940724 PMID:32184358 PMID:32805266 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Perp |
p53 apoptosis effector related to PMP22 |
affects expression |
ISO |
enzalutamide affects the expression of PERP mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 1:13,542,067...13,554,514
Ensembl chr 1:13,542,067...13,554,511
|
|
G |
Pla2g5 |
phospholipase A2, group V |
decreases expression |
ISO |
enzalutamide results in decreased expression of PLA2G5 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658
|
|
G |
Plk1 |
polo-like kinase 1 |
multiple interactions |
ISO |
[enzalutamide co-treated with NVP-BHG712] results in decreased expression of PLK1 mRNA; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of PLK1 protein; enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of PLK1 mRNA] |
CTD |
PMID:32184358 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Plod2 |
procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 |
decreases expression |
ISO |
enzalutamide results in decreased expression of PLOD2 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 8:93,084,548...93,167,255
Ensembl chr 8:93,084,513...93,167,255
|
|
G |
Pofut1 |
protein O-fucosyltransferase 1 |
affects expression |
ISO |
enzalutamide affects the expression of POFUT1 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 3:141,708,618...141,735,558
Ensembl chr 3:141,708,644...141,734,786
|
|
G |
Psen1 |
presenilin 1 |
affects expression |
ISO |
enzalutamide affects the expression of PSEN1 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 6:103,323,014...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Psen2 |
presenilin 2 |
affects expression |
ISO |
enzalutamide affects the expression of PSEN2 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr13:91,967,506...91,993,240
Ensembl chr13:91,967,983...91,993,174
|
|
G |
Psenen |
presenilin enhancer gamma secretase subunit |
affects expression |
ISO |
enzalutamide affects the expression of PSENEN mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 1:85,814,905...85,816,654
Ensembl chr 1:85,814,905...85,816,192
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
decreases expression |
ISO |
enzalutamide results in decreased expression of PTGER4 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
|
|
G |
Rbm15 |
RNA binding motif protein 15 |
affects expression |
ISO |
enzalutamide affects the expression of RBM15 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 2:194,945,717...194,954,523
Ensembl chr 2:194,945,974...194,954,703
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
affects expression |
ISO |
enzalutamide affects the expression of RBPJ mRNA |
CTD |
PMID:30940724 |
|
NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
decreases expression |
ISO |
enzalutamide results in decreased expression of RGS2 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
|
|
G |
Rhou |
ras homolog family member U |
decreases expression |
ISO |
enzalutamide results in decreased expression of RHOU mRNA |
CTD |
PMID:29581250 |
|
NCBI chr19:51,641,408...51,651,249
Ensembl chr19:51,641,227...51,650,552
|
|
G |
Rps19 |
ribosomal protein S19 |
affects expression |
ISO |
enzalutamide affects the expression of RPS19 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 1:80,480,718...80,486,511
Ensembl chr 1:80,480,951...80,486,508
|
|
G |
Rps27a |
ribosomal protein S27a |
affects expression |
ISO |
enzalutamide affects the expression of RPS27A mRNA |
CTD |
PMID:30940724 |
|
NCBI chr14:103,285,734...103,288,011
Ensembl chr14:103,285,734...103,288,011
|
|
G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
affects expression |
ISO |
enzalutamide affects the expression of S1PR3 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr17:13,781,050...13,794,408
Ensembl chr17:13,781,050...13,794,505
|
|
G |
Sel1l |
SEL1L adaptor subunit of ERAD E3 ubiquitin ligase |
affects expression |
ISO |
enzalutamide affects the expression of SEL1L mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 6:110,735,450...110,779,695
Ensembl chr 6:110,735,450...110,779,648
|
|
G |
Selenop |
selenoprotein P |
decreases expression |
ISO |
enzalutamide results in decreased expression of SELENOP mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 2:52,498,123...52,508,409
Ensembl chr 2:52,498,339...52,508,852
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions decreases expression |
ISO |
KDM1A protein promotes the reaction [enzalutamide results in decreased expression of SLC22A3 mRNA] |
CTD |
PMID:29581250 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Snw1 |
SNW domain containing 1 |
affects expression |
ISO |
enzalutamide affects the expression of SNW1 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 6:107,095,450...107,119,536
Ensembl chr 6:107,095,457...107,119,536
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
decreases expression |
ISO |
enzalutamide results in decreased expression of SOCS2 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
affects expression |
ISO |
enzalutamide affects the expression of SOX9 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Spen |
spen family transcriptional repressor |
affects expression |
ISO |
enzalutamide affects the expression of SPEN mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 5:153,775,287...153,848,677
Ensembl chr 5:153,776,234...153,848,811
|
|
G |
Spock1 |
sparc/osteonectin, cwcv and kazal like domains proteoglycan 1 |
decreases expression |
ISO |
enzalutamide results in decreased expression of SPOCK1 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr17:6,741,504...7,221,685
Ensembl chr17:6,742,273...7,224,935
|
|
G |
St6galnac1 |
ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 |
decreases expression |
ISO |
enzalutamide results in decreased expression of ST6GALNAC1 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr10:101,972,656...101,983,053
Ensembl chr10:101,972,668...101,983,053
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases response to substance |
ISO |
enzalutamide promotes the reaction [Niclosamide results in decreased phosphorylation of and results in decreased activity of STAT3 protein]; Niclosamide inhibits the reaction [STAT3 protein results in decreased susceptibility to enzalutamide] |
CTD |
PMID:25970160 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Susd5 |
sushi domain containing 5 |
affects expression |
ISO |
enzalutamide affects the expression of SUSD5 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 8:113,996,771...114,036,133
Ensembl chr 8:113,997,362...114,035,861
|
|
G |
Suz12 |
SUZ12 polycomb repressive complex 2 subunit |
multiple interactions decreases expression |
ISO |
[enzalutamide co-treated with GSK-2816126] inhibits the reaction [AR protein binds to [EZH2 protein binds to SUZ12 protein binds to EED protein]]; enzalutamide promotes the reaction [GSK-2816126 results in decreased expression of SUZ12 protein]; GSK-2816126 promotes the reaction [enzalutamide results in decreased expression of SUZ12 protein] |
CTD |
PMID:32805266 |
|
NCBI chr10:64,967,035...65,012,916
Ensembl chr10:64,966,967...65,012,738
|
|
G |
Tenm1 |
teneurin transmembrane protein 1 |
decreases expression |
ISO |
enzalutamide results in decreased expression of TENM1 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr X:121,400,466...122,289,877
Ensembl chr X:121,403,649...122,290,207
|
|
G |
Tmcc3 |
transmembrane and coiled-coil domain family 3 |
decreases expression multiple interactions |
ISO |
enzalutamide results in decreased expression of TMCC3 mRNA KDM1A protein promotes the reaction [enzalutamide results in decreased expression of TMCC3 mRNA] |
CTD |
PMID:29581250 |
|
NCBI chr 7:28,893,972...29,171,935
Ensembl chr 7:28,893,967...29,171,926
|
|
G |
Tpd52 |
tumor protein D52 |
decreases expression |
ISO |
enzalutamide results in decreased expression of TPD52 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 2:92,735,246...92,816,079
Ensembl chr 2:92,735,620...92,816,622
|
|
G |
Trpm8 |
transient receptor potential cation channel, subfamily M, member 8 |
decreases expression |
ISO |
enzalutamide results in decreased expression of TRPM8 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 9:88,897,039...88,990,167
Ensembl chr 9:88,903,880...88,988,552
|
|
G |
Uba52 |
ubiquitin A-52 residue ribosomal protein fusion product 1 |
affects expression |
ISO |
enzalutamide affects the expression of UBA52 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr16:18,918,614...18,920,807
Ensembl chr16:18,900,616...18,920,807
|
|
G |
Ubb |
ubiquitin B |
affects expression |
ISO |
enzalutamide affects the expression of UBB mRNA |
CTD |
PMID:30940724 |
|
NCBI chr10:47,247,629...47,249,335
Ensembl chr10:47,245,637...47,249,333
|
|
G |
Ubc |
ubiquitin C |
affects expression |
ISO |
enzalutamide affects the expression of UBC mRNA |
CTD |
PMID:30940724 |
|
NCBI chr12:31,238,889...31,243,924
Ensembl chr12:31,239,152...31,243,925
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
multiple interactions |
ISO |
[enzalutamide co-treated with NVP-BHG712] results in decreased expression of UBE2C mRNA |
CTD |
PMID:32184358 |
|
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
|
|
G |
Wdr12 |
WD repeat domain 12 |
affects expression |
ISO |
enzalutamide affects the expression of WDR12 mRNA |
CTD |
PMID:30940724 |
|
NCBI chr 9:61,475,498...61,502,584
Ensembl chr 9:61,475,517...61,502,469
|
|
G |
Wwtr1 |
WW domain containing transcription regulator 1 |
decreases expression |
ISO |
enzalutamide results in decreased expression of WWTR1 mRNA |
CTD |
PMID:29581250 |
|
NCBI chr 2:141,651,159...141,766,919
Ensembl chr 2:141,648,108...141,766,968
|
|
|
G |
Aass |
aminoadipate-semialdehyde synthase |
decreases expression |
ISO |
epoxiconazole results in decreased expression of AASS mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 4:51,606,461...51,663,136
Ensembl chr 4:51,606,462...51,663,136
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCB11 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of ABCB11 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
EXP |
epoxiconazole results in increased expression of ABCB1A mRNA [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCB1A mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of ABCB1A mRNA |
CTD |
PMID:25182419 PMID:29038839 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
increases expression |
EXP |
epoxiconazole results in increased expression of ABCB1B mRNA |
CTD |
PMID:25182419 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression multiple interactions |
EXP |
epoxiconazole results in increased expression of ABCC2 mRNA [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCC2 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression multiple interactions |
ISO EXP |
epoxiconazole results in increased expression of ABCC3 mRNA [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCC3 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of ABCC3 mRNA |
CTD |
PMID:22334560 PMID:29038839 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression |
ISO |
epoxiconazole results in increased expression of ABCC4 mRNA |
CTD |
PMID:22334560 PMID:23970803 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abhd4 |
abhydrolase domain containing 4, N-acyl phospholipase B |
increases expression |
ISO |
epoxiconazole results in increased expression of ABHD4 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr15:27,697,384...27,716,013
Ensembl chr15:27,704,113...27,716,966
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole] results in increased expression of ABL1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of ACAA2 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Acad9 |
acyl-CoA dehydrogenase family, member 9 |
increases expression |
EXP |
epoxiconazole results in increased expression of ACAD9 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 2:118,943,170...118,966,150
Ensembl chr 2:118,943,174...118,966,547
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of ACAT1 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole] results in increased expression of ACAT2 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Acly |
ATP citrate lyase |
increases expression |
EXP |
epoxiconazole results in increased expression of ACLY mRNA |
CTD |
PMID:29038839 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Aco1 |
aconitase 1 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ACO1 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of ACO1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
|
|
G |
Acot3 |
acyl-CoA thioesterase 3 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ACOT3 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 6:103,682,518...103,688,735
Ensembl chr 6:103,682,596...103,688,427
|
|
G |
Acot9 |
acyl-CoA thioesterase 9 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ACOT9 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr X:40,073,197...40,123,573
Ensembl chr X:40,064,810...40,123,559
|
|
G |
Acp2 |
acid phosphatase 2, lysosomal |
increases expression |
ISO |
epoxiconazole results in increased expression of ACP2 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 3:77,175,022...77,185,180
Ensembl chr 3:77,175,895...77,185,680
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of ACSL1 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Actn1 |
actinin, alpha 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ACTN1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G |
Adam11 |
ADAM metallopeptidase domain 11 |
increases expression |
ISO |
epoxiconazole results in increased expression of ADAM11 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr10:87,724,115...87,742,773
Ensembl chr10:87,724,234...87,741,562
|
|
G |
Adh1 |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
decreases expression |
EXP |
epoxiconazole results in decreased expression of ADH1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adss1 |
adenylosuccinate synthase 1 |
increases expression |
ISO |
epoxiconazole results in increased expression of ADSSL1 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 6:131,679,795...131,702,012
Ensembl chr 6:131,679,701...131,701,998
|
|
G |
Ahctf1 |
AT hook containing transcription factor 1 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of AHCTF1 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr13:91,481,932...91,536,391
Ensembl chr13:91,481,936...91,536,391
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression |
ISO EXP |
epoxiconazole results in increased expression of AHR mRNA |
CTD |
PMID:22334560 PMID:25182419 PMID:29038839 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ahsg |
alpha-2-HS-glycoprotein |
decreases expression |
ISO |
epoxiconazole results in decreased expression of AHSG mRNA |
CTD |
PMID:22334560 |
|
NCBI chr11:78,117,903...78,145,956
Ensembl chr11:78,117,918...78,145,999
|
|
G |
Akap1 |
A-kinase anchoring protein 1 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of AKAP1 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr10:73,621,021...73,654,123
Ensembl chr10:73,621,883...73,653,896
|
|
G |
Akap13 |
A-kinase anchoring protein 13 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of AKAP13 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 1:129,313,183...129,619,647
Ensembl chr 1:129,314,402...129,619,646
|
|
G |
Akap9 |
A-kinase anchoring protein 9 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of AKAP9 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 4:30,056,738...30,192,716
Ensembl chr 4:30,056,738...30,192,606
|
|
G |
Akr1b7 |
aldo-keto reductase family 1, member B7 |
increases expression |
ISO |
epoxiconazole results in increased expression of AKR1B7 mRNA |
CTD |
PMID:22334560 PMID:23970803 |
|
NCBI chr 4:63,053,560...63,100,934
Ensembl chr 4:63,076,800...63,089,502
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression multiple interactions |
EXP |
epoxiconazole results in increased expression of ALDH1A1 mRNA [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ALDH1A1 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:25182419 PMID:29038839 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Als2 |
alsin Rho guanine nucleotide exchange factor ALS2 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of ALS2 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 9:60,613,182...60,686,394
Ensembl chr 9:60,613,167...60,670,737
|
|
G |
Anxa10 |
annexin A10 |
increases expression |
ISO |
epoxiconazole results in increased expression of ANXA10 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648
|
|
G |
Anxa7 |
annexin A7 |
increases expression |
ISO |
epoxiconazole results in increased expression of ANXA7 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr15:3,821,798...3,849,659
Ensembl chr15:3,821,845...3,849,385
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of APEX1 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of APEX1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Apoe |
apolipoprotein E |
increases expression |
EXP |
epoxiconazole results in increased expression of APOE mRNA |
CTD |
PMID:28454766 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Apof |
apolipoprotein F |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole] results in increased expression of APOF mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 7:700,688...702,130
Ensembl chr 7:700,762...701,946
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
epoxiconazole inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:18324785 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arg1 |
arginase 1 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of ARG1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arl5a |
ADP-ribosylation factor like GTPase 5A |
decreases expression |
ISO |
epoxiconazole results in decreased expression of ARL5A mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 3:36,878,461...36,903,362
Ensembl chr 3:36,880,712...36,903,211
|
|
G |
Arpp19 |
cAMP-regulated phosphoprotein 19 |
increases expression |
ISO |
epoxiconazole results in increased expression of ARPP19 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 8:75,779,640...75,802,474
Ensembl chr 8:75,779,523...75,802,452
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
increases expression |
ISO |
epoxiconazole results in increased expression of ASAH1 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ASNS mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atf5 |
activating transcription factor 5 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of ATF5 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole] results in increased expression of ATF6 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atg16l2 |
autophagy related 16-like 2 |
increases expression |
ISO |
epoxiconazole results in increased expression of ATG16L2 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 1:155,687,386...155,703,419
Ensembl chr 1:155,684,564...155,703,420
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases expression |
EXP |
[cyproconazole co-treated with epoxiconazole] results in increased expression of ATM mRNA epoxiconazole results in increased expression of ATM mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp6v0e1 |
ATPase H+ transporting V0 subunit e1 |
increases expression |
ISO |
epoxiconazole results in increased expression of ATP6V0E mRNA |
CTD |
PMID:22334560 |
|
NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
multiple interactions increases expression |
EXP |
[cyproconazole co-treated with epoxiconazole] results in increased expression of ATP8B1 mRNA epoxiconazole results in increased expression of ATP8B1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Atxn7l3b |
ataxin 7-like 3B |
decreases expression |
ISO |
epoxiconazole results in decreased expression of ATXN7L3B mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 7:48,322,451...48,325,975
Ensembl chr 7:48,321,755...48,328,878
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of BACE1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bace2 |
beta-secretase 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of BACE2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr11:36,707,473...36,789,550
Ensembl chr11:36,707,458...36,789,546
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of BDNF mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bhmt2 |
betaine-homocysteine S-methyltransferase 2 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of BHMT2 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 2:24,895,525...24,912,475
Ensembl chr 2:24,895,533...24,912,475
|
|
G |
Bid |
BH3 interacting domain death agonist |
decreases expression |
ISO |
epoxiconazole results in decreased expression of BID mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bsn |
bassoon (presynaptic cytomatrix protein) |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of BSN mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 8:108,784,849...108,875,819
Ensembl chr 8:108,788,542...108,875,819
|
|
G |
C2cd2 |
C2 calcium-dependent domain containing 2 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of C2CD2 mRNA |
CTD |
PMID:22334560 PMID:23970803 |
|
NCBI chr11:37,225,321...37,289,741
Ensembl chr11:37,227,415...37,289,739
|
|
G |
C4b |
complement C4B (Chido blood group) |
decreases expression |
ISO |
epoxiconazole results in decreased expression of C4B mRNA |
CTD |
PMID:22334560 |
|
NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1A mRNA |
CTD |
PMID:25607892 |
|
NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
|
|
G |
Cacna1b |
calcium voltage-gated channel subunit alpha1 B |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1B mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:7,380,892...7,546,104
Ensembl chr 3:7,380,922...7,546,091
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1C mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
|
|
G |
Cacna1d |
calcium voltage-gated channel subunit alpha1 D |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1D mRNA |
CTD |
PMID:25607892 |
|
NCBI chr16:5,227,157...5,521,163
Ensembl chr16:5,228,306...5,668,215
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1G mRNA |
CTD |
PMID:25607892 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNA1I mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688
|
|
G |
Cacna2d3 |
calcium voltage-gated channel auxiliary subunit alpha2delta 3 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CACNA2D3 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr16:4,098,439...4,912,498
Ensembl chr16:4,098,445...4,912,351
|
|
G |
Cacnb1 |
calcium voltage-gated channel auxiliary subunit beta 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNB1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr10:82,998,182...83,018,838
Ensembl chr10:82,998,182...83,018,694
|
|
G |
Cacnb3 |
calcium voltage-gated channel auxiliary subunit beta 3 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNB3 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:129,784,799...129,797,074
Ensembl chr 7:129,783,674...129,797,074
|
|
G |
Cacng2 |
calcium voltage-gated channel auxiliary subunit gamma 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:109,572,838...109,698,516
Ensembl chr 7:109,574,459...109,697,227
|
|
G |
Cacng6 |
calcium voltage-gated channel auxiliary subunit gamma 6 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG6 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:65,732,910...65,747,377
Ensembl chr 1:65,732,632...65,747,341
|
|
G |
Cacng7 |
calcium voltage-gated channel auxiliary subunit gamma 7 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNG7 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:65,800,820...65,831,165
Ensembl chr 1:65,800,355...65,831,006
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CADM1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CAMK2B mRNA |
CTD |
PMID:25607892 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CAMK2G mRNA |
CTD |
PMID:25607892 |
|
NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050
|
|
G |
Capns1 |
calpain, small subunit 1 |
increases expression |
ISO |
epoxiconazole results in increased expression of CAPNS1 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 1:85,444,613...85,454,861
Ensembl chr 1:85,444,608...85,454,795
|
|
G |
Cars |
cysteinyl-tRNA synthetase |
decreases expression |
ISO |
epoxiconazole results in decreased expression of CARS mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole] results in increased expression of CASP7 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO EXP |
epoxiconazole results in increased expression of CD36 mRNA [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CD36 mRNA |
CTD |
PMID:22334560 PMID:29038839 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CD44 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd81 |
Cd81 molecule |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CD81 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:198,235,861...198,251,660
Ensembl chr 1:198,241,484...198,251,660
|
|
G |
Cdc34 |
cell division cycle 34, ubiqiutin conjugating enzyme |
increases expression |
ISO |
epoxiconazole results in increased expression of CDC34 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 7:10,017,588...10,023,586
Ensembl chr 7:10,017,588...10,023,186
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in decreased expression of CDKN1A mRNA; [cyproconazole co-treated with epoxiconazole] results in decreased expression of CDKN1A mRNA |
CTD |
PMID:29038839 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cds2 |
CDP-diacylglycerol synthase 2 |
increases expression |
ISO |
epoxiconazole results in increased expression of CDS2 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 3:119,514,963...119,553,555
Ensembl chr 3:119,515,000...119,553,541
|
|
G |
Cebpz |
CCAAT/enhancer binding protein zeta |
decreases expression |
ISO |
epoxiconazole results in decreased expression of CEBPZ mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 6:16,119,871...16,137,600
Ensembl chr 6:16,119,872...16,137,600
|
|
G |
Ces2c |
carboxylesterase 2C |
increases expression multiple interactions |
EXP |
epoxiconazole results in increased expression of CES2C mRNA [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CES2C mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of CES2C mRNA |
CTD |
PMID:25182419 PMID:29038839 |
|
NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790
|
|
G |
Ces2h |
carboxylesterase 2H |
increases expression |
ISO |
epoxiconazole results in increased expression of CES2 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cggbp1 |
CGG triplet repeat binding protein 1 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of CGGBP1 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr11:2,565,629...2,572,869
Ensembl chr11:2,565,484...2,573,031
|
|
G |
Chd1l |
chromodomain helicase DNA binding protein 1-like |
increases expression |
ISO |
epoxiconazole results in increased expression of CHD1L mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 2:185,138,526...185,217,498
Ensembl chr 2:185,139,308...185,217,595
|
|
G |
Chga |
chromogranin A |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CHGA mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398
|
|
G |
Chka |
choline kinase alpha |
decreases expression |
ISO |
epoxiconazole results in decreased expression of CHKA mRNA |
CTD |
PMID:22334560 PMID:23970803 |
|
NCBI chr 1:201,076,804...201,125,517
Ensembl chr 1:201,076,860...201,125,516
|
|
G |
Chst1 |
carbohydrate sulfotransferase 1 |
decreases expression |
EXP |
epoxiconazole results in decreased expression of CHST1 mRNA |
CTD |
PMID:25182419 |
|
NCBI chr 3:78,552,059...78,574,736
Ensembl chr 3:78,548,525...78,574,883
|
|
G |
Cmahp |
cytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogene |
decreases expression |
ISO |
epoxiconazole results in decreased expression of CMAH mRNA |
CTD |
PMID:22334560 |
|
NCBI chr17:40,557,161...40,642,350
Ensembl chr17:40,583,667...40,642,275
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole] results in increased expression of COMT mRNA |
CTD |
PMID:29038839 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CPT2 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Creg1 |
cellular repressor of E1A-stimulated genes 1 |
increases expression |
ISO |
epoxiconazole results in increased expression of CREG1 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr13:78,019,814...78,032,310
Ensembl chr13:78,019,843...78,032,308
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
epoxiconazole results in increased expression of CRP mRNA |
CTD |
PMID:22334560 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Ctsd |
cathepsin D |
increases expression |
ISO |
epoxiconazole results in increased expression of CTSD mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctse |
cathepsin E |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole] results in increased expression of CTSE mRNA |
CTD |
PMID:29038839 |
|
NCBI chr13:43,091,954...43,114,509
Ensembl chr13:43,092,128...43,114,502
|
|
G |
Ctsl |
cathepsin L |
increases expression |
ISO |
epoxiconazole results in increased expression of CTSL mRNA |
CTD |
PMID:22334560 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Ctso |
cathepsin O |
increases expression |
ISO |
epoxiconazole results in increased expression of CTSO mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 2:167,230,407...167,254,761
Ensembl chr 2:167,230,330...167,253,702
|
|
G |
Cyb5a |
cytochrome b5 type A |
increases expression |
ISO |
epoxiconazole results in increased expression of CYB5A mRNA |
CTD |
PMID:22334560 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in decreased expression of CYP11B1 mRNA |
CTD |
PMID:28454766 |
|
NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
increases expression |
EXP |
epoxiconazole results in increased expression of CYP11B2 mRNA |
CTD |
PMID:28454766 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
ISO EXP |
[prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased expression of CYP19A1 mRNA [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:25233012 PMID:25607892 |
|
NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression multiple interactions increases activity |
EXP ISO |
epoxiconazole results in increased expression of CYP1A1 mRNA [epoxiconazole co-treated with cyproconazole] results in increased activity of CYP1A1 protein; [epoxiconazole co-treated with cyproconazole] results in increased expression of CYP1A1 mRNA; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased activity of CYP1A1 protein; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased expression of CYP1A1 mRNA epoxiconazole results in increased activity of CYP1A1 protein epoxiconazole results in increased expression of CYP1A1 mRNA; epoxiconazole results in increased expression of CYP1A1 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [epoxiconazole results in increased expression of CYP1A1 mRNA]; [fluxapyroxad co-treated with epoxiconazole] results in increased expression of CYP1A1 mRNA; [fluxapyroxad co-treated with epoxiconazole] results in increased expression of CYP1A1 protein |
CTD |
PMID:25182419 PMID:25233012 PMID:29038839 PMID:29294346 PMID:32194361 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO |
epoxiconazole results in increased expression of CYP1A2 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression multiple interactions increases activity |
ISO EXP |
epoxiconazole results in increased expression of CYP2B10 mRNA [cyproconazole co-treated with epoxiconazole] results in increased expression of CYP2B1 mRNA; [epoxiconazole co-treated with cyproconazole] results in increased activity of CYP2B1 protein; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased activity of CYP2B1 protein; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased expression of CYP2B1 mRNA epoxiconazole results in increased activity of CYP2B1 protein epoxiconazole results in increased expression of CYP2B1 mRNA |
CTD |
PMID:22334560 PMID:23970803 PMID:25182419 PMID:29038839 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b15 |
cytochrome P450, family 2, subfamily b, polypeptide 15 |
increases expression |
EXP |
epoxiconazole results in increased expression of CYP2B15 mRNA |
CTD |
PMID:25182419 |
|
NCBI chr 1:82,094,188...82,106,492
Ensembl chr 1:82,094,180...82,106,492
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression multiple interactions |
EXP |
epoxiconazole results in increased expression of CYP2B2 mRNA [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CYP2B2 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of CYP2B2 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression multiple interactions |
ISO |
epoxiconazole results in increased expression of CYP2B9 mRNA [fluxapyroxad co-treated with epoxiconazole] results in increased expression of CYP2B6 mRNA; [fluxapyroxad co-treated with epoxiconazole] results in increased expression of CYP2B6 protein |
CTD |
PMID:22334560 PMID:23970803 PMID:29294346 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases expression |
EXP |
epoxiconazole results in increased expression of CYP2C11 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
increases expression |
ISO |
epoxiconazole results in increased expression of CYP2C55 mRNA |
CTD |
PMID:22334560 PMID:23970803 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
increases expression decreases expression |
EXP ISO |
epoxiconazole results in increased expression of CYP2C6V1 mRNA epoxiconazole results in decreased expression of CYP2C19 protein |
CTD |
PMID:25182419 PMID:32194361 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole] results in increased expression of CYP2E1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression multiple interactions |
EXP ISO |
epoxiconazole results in increased expression of CYP3A2 mRNA [fluxapyroxad co-treated with epoxiconazole] results in increased expression of CYP3A4 mRNA; [fluxapyroxad co-treated with epoxiconazole] results in increased expression of CYP3A4 protein epoxiconazole results in increased expression of CYP3A4 mRNA; epoxiconazole results in increased expression of CYP3A4 protein [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CYP3A2 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of CYP3A2 mRNA |
CTD |
PMID:29038839 PMID:29294346 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression multiple interactions increases activity |
EXP |
epoxiconazole results in increased expression of CYP3A23-3A1 mRNA [cyproconazole co-treated with epoxiconazole] results in increased expression of CYP3A23-3A1 mRNA; [epoxiconazole co-treated with cyproconazole] results in increased activity of CYP3A23-3A1 protein; [prochloraz co-treated with cyproconazole co-treated with epoxiconazole] results in increased expression of CYP3A23-3A1 mRNA; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased activity of CYP3A23-3A1 protein epoxiconazole results in increased activity of CYP3A23-3A1 protein |
CTD |
PMID:25182419 PMID:29038839 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
increases expression |
EXP |
epoxiconazole results in increased expression of CYP4B1 mRNA |
CTD |
PMID:25182419 |
|
NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases activity |
ISO |
epoxiconazole results in decreased activity of CYP51A1 protein |
CTD |
PMID:16989930 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions decreases expression |
EXP ISO |
[cyproconazole co-treated with epoxiconazole] results in increased expression of CYP7A1 mRNA epoxiconazole results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:29038839 PMID:32194361 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Dbt |
dihydrolipoamide branched chain transacylase E2 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of DBT mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 2:204,481,744...204,510,612
Ensembl chr 2:204,481,737...204,510,609
|
|
G |
Dcc |
DCC netrin 1 receptor |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DCC mRNA |
CTD |
PMID:25607892 |
|
NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740
|
|
G |
Ddost |
dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit |
increases expression |
ISO |
epoxiconazole results in increased expression of DDOST mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 5:150,522,297...150,529,413
Ensembl chr 5:150,522,242...150,529,413
|
|
G |
Ddx46 |
DEAD-box helicase 46 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of DDX46 mRNA |
CTD |
PMID:22334560 PMID:23970803 |
|
NCBI chr17:8,944,197...8,988,476
Ensembl chr17:8,944,454...8,988,439
|
|
G |
Ddx6 |
DEAD-box helicase 6 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of DDX6 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 8:44,931,127...44,967,773
Ensembl chr 8:44,931,974...44,964,405
|
|
G |
Dexi |
Dexi homolog |
decreases expression |
ISO |
epoxiconazole results in decreased expression of DEXI mRNA |
CTD |
PMID:22334560 |
|
NCBI chr10:5,126,021...5,138,746
Ensembl chr10:5,137,288...5,138,738
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole] results in increased expression of DIABLO mRNA |
CTD |
PMID:29038839 |
|
NCBI chr12:33,055,784...33,070,400
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Dlat |
dihydrolipoamide S-acetyltransferase |
increases expression |
EXP |
epoxiconazole results in increased expression of DLAT mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479
|
|
G |
Dlg1 |
discs large MAGUK scaffold protein 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DLG1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of DLG4 mRNA; [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DLG4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153
|
|
G |
Dlgap3 |
DLG associated protein 3 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DLGAP3 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 5:139,491,972...139,562,625
Ensembl chr 5:139,492,947...139,562,625
|
|
G |
Dlgap4 |
DLG associated protein 4 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DLGAP4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:145,124,189...145,271,791
Ensembl chr 3:145,175,479...145,270,490
|
|
G |
Dmgdh |
dimethylglycine dehydrogenase |
decreases expression |
ISO |
epoxiconazole results in decreased expression of DMGDH mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 2:24,912,600...24,987,533
Ensembl chr 2:24,912,578...24,987,528
|
|
G |
Dnai1 |
dynein, axonemal, intermediate chain 1 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of DNAI1 mRNA |
CTD |
PMID:22334560 PMID:23970803 |
|
NCBI chr 5:56,730,179...56,800,926
Ensembl chr 5:56,730,179...56,800,925
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
increases expression |
EXP |
epoxiconazole results in increased expression of DNAJB1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr19:24,522,717...24,526,458
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Doc2a |
double C2 domain alpha |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DOC2A mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:181,457,415...181,462,528
Ensembl chr 1:181,458,390...181,462,030
|
|
G |
Dpagt1 |
dolichyl-phosphate N-acetylglucosaminephosphotransferase 1 |
increases expression |
ISO |
epoxiconazole results in increased expression of DPAGT1 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 8:44,664,055...44,671,102
Ensembl chr 8:44,664,071...44,671,087
|
|
G |
Dpp10 |
dipeptidyl peptidase like 10 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DPP10 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr13:34,584,420...36,269,619
Ensembl chr13:34,595,868...36,269,292
|
|
G |
Dpp6 |
dipeptidyl peptidase like 6 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DPP6 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 4:7,589,386...8,508,666
Ensembl chr 4:7,591,009...8,508,532
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DPYD mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
|
|
G |
Dusp3 |
dual specificity phosphatase 3 |
increases expression |
ISO |
epoxiconazole results in increased expression of DUSP3 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr10:86,920,014...86,933,739
Ensembl chr10:86,920,014...86,933,962
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGF mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA |
CTD |
PMID:25607892 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
EXP |
epoxiconazole results in decreased expression of EGR1 mRNA |
CTD |
PMID:28454766 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Ehd1 |
EH-domain containing 1 |
decreases expression |
EXP |
epoxiconazole results in decreased expression of EHD1 mRNA |
CTD |
PMID:28454766 |
|
NCBI chr 1:203,579,850...203,602,226
Ensembl chr 1:203,579,869...203,602,212
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of EHHADH mRNA |
CTD |
PMID:29038839 |
|
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases expression multiple interactions |
EXP |
epoxiconazole results in increased expression of EIF2AK3 mRNA [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of EIF2AK3 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif4g2 |
eukaryotic translation initiation factor 4, gamma 2 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of EIF4G2 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 1:165,181,433...165,193,583
Ensembl chr 1:165,181,434...165,193,588
|
|
G |
Elovl1 |
ELOVL fatty acid elongase 1 |
increases expression |
ISO |
epoxiconazole results in increased expression of ELOVL1 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958
|
|
G |
Enho |
energy homeostasis associated |
decreases expression |
ISO |
epoxiconazole results in decreased expression of ENHO mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 5:56,800,980...56,802,777
Ensembl chr 5:56,800,980...56,802,777
|
|
G |
Entpd5 |
ectonucleoside triphosphate diphosphohydrolase 5 |
increases expression |
ISO |
epoxiconazole results in increased expression of ENTPD5 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 6:104,019,095...104,055,311
Ensembl chr 6:104,019,185...104,055,530
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of EP300 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression multiple interactions |
ISO EXP |
epoxiconazole results in increased expression of EPHX1 mRNA [cyproconazole co-treated with epoxiconazole] results in increased expression of EPHX1 mRNA |
CTD |
PMID:22334560 PMID:25182419 PMID:29038839 |
|
NCBI chr13:92,714,315...92,744,124
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of EPHX2 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB4 mRNA; [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ERCC1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Etfa |
electron transfer flavoprotein subunit alpha |
decreases expression |
ISO |
epoxiconazole results in decreased expression of ETFA mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 8:55,835,115...55,891,890
Ensembl chr 8:55,835,134...55,891,969
|
|
G |
Etnppl |
ethanolamine-phosphate phospho-lyase |
decreases expression |
ISO |
epoxiconazole results in decreased expression of ETNPPL mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 2:219,173,048...219,194,646
Ensembl chr 2:219,172,978...219,192,212
|
|
G |
Exosc8 |
exosome component 8 |
increases expression |
ISO |
epoxiconazole results in increased expression of EXOSC8 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 2:138,930,405...138,937,009
Ensembl chr 2:138,930,405...138,936,928
|
|
G |
F10 |
coagulation factor X |
increases expression |
ISO |
epoxiconazole results in increased expression of F10 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F5 |
coagulation factor V |
decreases expression |
ISO |
epoxiconazole results in decreased expression of F5 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr13:76,513,463...76,583,106
Ensembl chr13:76,513,255...76,582,317
|
|
G |
Fah |
fumarylacetoacetate hydrolase |
decreases expression |
ISO |
epoxiconazole results in decreased expression of FAH mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 1:138,548,830...138,571,599
Ensembl chr 1:138,548,834...138,571,505
|
|
G |
Fam114a1 |
family with sequence similarity 114, member A1 |
increases expression |
ISO |
epoxiconazole results in increased expression of FAM114A1 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr14:43,275,693...43,346,227
Ensembl chr14:43,275,701...43,346,174
|
|
G |
Fam168a |
family with sequence similarity 168, member A |
decreases expression |
ISO |
epoxiconazole results in decreased expression of FAM168A mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 1:155,057,352...155,203,439
Ensembl chr 1:155,057,352...155,201,220
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of FAS mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
EXP |
epoxiconazole results in increased expression of FASN mRNA |
CTD |
PMID:29038839 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fez2 |
fasciculation and elongation protein zeta 2 |
increases expression |
ISO |
epoxiconazole results in increased expression of FEZ2 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 6:16,654,572...16,694,628
Ensembl chr 6:16,654,614...16,694,626
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of FGF1 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FMR1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FYN mRNA |
CTD |
PMID:25607892 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
G3bp2 |
G3BP stress granule assembly factor 2 |
increases expression |
ISO |
epoxiconazole results in increased expression of G3BP2 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr14:15,932,356...16,020,555
Ensembl chr14:15,987,417...16,020,548
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of G6PC1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GABRA4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr14:36,590,782...36,667,724
Ensembl chr14:36,590,782...36,665,844
|
|
G |
Gabrb1 |
gamma-aminobutyric acid type A receptor subunit beta1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GABRB1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression |
ISO |
epoxiconazole results in increased expression of GADD45B mRNA |
CTD |
PMID:22334560 PMID:23970803 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
increases expression |
ISO |
epoxiconazole results in increased expression of GCH1 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GDNF mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:56,893,992...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Ghr |
growth hormone receptor |
decreases expression |
ISO |
epoxiconazole results in decreased expression of GHR mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735
|
|
G |
Glrx |
glutaredoxin |
increases expression |
ISO |
epoxiconazole results in increased expression of GLRX mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Glrx5 |
glutaredoxin 5 |
increases expression |
ISO |
epoxiconazole results in increased expression of GLRX5 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 6:123,988,169...123,998,545
Ensembl chr 6:123,988,134...123,998,545
|
|
G |
Gls |
glutaminase |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GLS mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gls2 |
glutaminase 2 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of GLS2 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 7:617,252...633,424
Ensembl chr 7:617,288...633,426
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
decreases expression |
ISO |
epoxiconazole results in decreased expression of GLUD1 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957
|
|
G |
Gpc1 |
glypican 1 |
decreases expression |
EXP |
epoxiconazole results in decreased expression of GPC1 mRNA |
CTD |
PMID:28454766 |
|
NCBI chr 9:93,396,234...93,424,047
Ensembl chr 9:93,396,234...93,424,047
|
|
G |
Gpd1 |
glycerol-3-phosphate dehydrogenase 1 |
increases expression |
EXP |
epoxiconazole results in increased expression of GPD1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole] results in increased expression of GPX2 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases expression |
ISO |
epoxiconazole results in increased expression of GPX4 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Gria4 |
glutamate ionotropic receptor AMPA type subunit 4 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 8:1,562,118...2,035,035
Ensembl chr 8:1,562,119...2,034,979
|
|
G |
Grik1 |
glutamate ionotropic receptor kainate type subunit 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of GRIK1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr11:27,169,739...27,571,131
Ensembl chr11:27,169,740...27,570,645
|
|
G |
Grik2 |
glutamate ionotropic receptor kainate type subunit 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIK2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of GRIN1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of GRIN2B mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Grip1 |
glutamate receptor interacting protein 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIP1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:54,934,856...55,592,274
Ensembl chr 7:54,934,250...55,592,273
|
|
G |
Grn |
granulin precursor |
decreases expression |
ISO |
epoxiconazole results in decreased expression of GRN mRNA |
CTD |
PMID:22334560 |
|
NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression |
EXP |
epoxiconazole results in increased expression of GSR mRNA |
CTD |
PMID:25182419 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression |
ISO |
epoxiconazole results in increased expression of GSTA2 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of GSTA5 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of GSTA5 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gsta6 |
glutathione S-transferase alpha 6 |
increases expression |
ISO |
epoxiconazole results in increased expression of GSTA2 mRNA |
CTD |
PMID:22334560 |
|
NCBI chr 9:23,743,262...23,806,260
Ensembl chr 9:23,744,288...23,801,131
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression |
EXP ISO |
epoxiconazole results in increased expression of GSTM1 mRNA |
CTD |
PMID:22334560 PMID:25182419 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
increases expression |
EXP ISO |
epoxiconazole results in increased expression of GSTM2 mRNA |
CTD |
PMID:22334560 PMID:25182419 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstm4 |
glutathione S-trans | |